Supporting Information

Rhodium-Catalyzed Carbonylative Coupling of Alkyl Halides with Phenols under Low CO Pressure

Han-Jun Ai, Hai Wang, Chong-Liang Li, and Xiao-Feng Wu*

Leibniz-Institut für Katalyse e.V. an der Universität Rostock, Albert-Einstein-Straße 29a, 18059 Rostock, Germany

xiao-feng.wu@catalysis.de

Table of Contents

General Remarks

Reagents and solvents: Unless otherwise noted, the chemicals were commercially available from Sigma-Aldrich, TCI or Alfa Aesar and were used without further purification. Dioxane bought from Alfa Aesar, HPLC grade, 99% min, packaged under argon in resealable ChemSeal bottles. The reaction does not require the glovebox.

Purification: The products were isolated from the reaction mixture by column chromatography on silica gel 60, 0.063-0.2 mm, 70-230 mesh (Merck). Gradient flash chromatography was conducted eluting with PE/EA, PE refers to pentane and EA refers to ethyl acetate, they were listed as volume/volume ratios.

Data collection: GC-yields were calculated using hexadecane as internal standard. GC analysis was performed on an Agilent HP-7890A instrument with FID detector and HP-5 capillary column (polydimethylsiloxane with 5% phenyl groups, 30 m, 0.32 mm i.d., 0.25 μm film thickness) using argon as carrier gas. High resolution mass spectra (HRMS) were recorded on Agilent 6210. NMR spectra were recorded on Bruker Avance 300 and Bruker ARX 400 spectrometers. Chemical shifts (ppm) are given relative to solvent: references for $CDCl_3$ were 7.26 ppm (^1H NMR) and 77.00 ppm (^{13}C NMR). All measurements were carried out at room temperature unless otherwise stated.

General Procedure for Optimization

Room temperature under air, Na_2CO_3 (0.2 mmol, 1 equiv), catalyst (0.01 mmol, 5 mol%), ligand (0.03 mmol, 15 mol%), phenol (0.2 mmol, 1 equiv) and additive were transferred into an 8-mL vial with a 1.0 cm stirring bar. Then adding dioxane (0.5 mL) with syringe and 1-iodobutane (0.32 mmol, 1.6 equiv) with micro syringe. The vial was then capped (with a needle) and placed in an aluminum rack within a Parr pressure reactor. Next, the reactor was closed and a CO gas cylinder with a pressure regulator was connected. The reactor was flushed with CO gas (5 bar; fill and released) three times and 1 bar of carbon monoxide (measured by pressure meter) was charged. Then

5 bar N_2 was pressurized to prevent solvent evaporation. The reaction was stirred at 120 ℃ with a stir rate at 550 rpm for 24 h. After cooling to room temperature, the CO gas was released and 10 μL of hexadecane as internal standard was added to the vial. The reaction mixture was then stirred for 5 min and a proper amount of solution was taken for GC analysis.

Table S1. Catalyst and ligand investigation



1 (1 equiv) + **2** (1.6 equiv) → **3**

Entry[a]	Catal.(mol%)	Ligand (mol%)	Yield (%)[b]
1	$Rh(CO)_2acac$ (5)	DPPP (15)	72
2	$[Rh(cod)OH]_2$ (2.5)	DPPP (15)	45
3	$[Rh(OAc)_2]_2$ (2.5)	DPPP (15)	49
4	$RhCl(PPh_3)_3$ (5)	DPPP (15)	57
5	$NiBr_2$•dme (5)	DPPP (15)	0
6	$PdCl_2$ (5)	DPPP (15)	Trace
7	$RhCl_3$ (5)	DPPE (15)	41
8	$RhCl_3$ (5)	DPPB (15)	41
9	$RhCl_3$ (5)	DPPF (15)	39
10	$RhCl_3$ (5)	Xantphos (15)	4
11	$RhCl_3$ (5)	PPh_3 (30)	29
12	$RhCl_3$ (5)	PCy_3 (30)	17

Table S2. Additive investigation



1 (1 equiv) + **2** (1.6 equiv) → **3**

Entry	Additive (10 mol%)	Yield (%)
1	NaCl	95
2	NaI	98
3	NaOAc	61
4	TBAB	89
5	KBr	90

General Procedure for Carbonylative Coupling



Room temperature under air, Na_2CO_3 (53 mg, 0.5 mmol, 1 equiv), $RhCl_3$ (5.2 mg, 0.025 mmol, 5 mol%), DPPP (30.9 mg, 0.075 mmol, 15 mol%), phenols (if solid) (0.5 mmol, 1 equiv), alkyl halide (if solid) (0.8 mmol, 1.6 equiv) and NaBr (if X = I) (5.1 mg, 0.05 mmol, 10 mol%) or NaI (if X = Br) (60 mg, 0.4 mmol, 80 mol%) were transferred into an 8-mL vial with a 1.0 cm stirring bar. Then adding dioxane (1.25 mL) with syringe and alkyl halide (if liquid) (0.8 mmol, 1.6 equiv) and phenol (if liquid) (0.5 mmol, 1 equiv) with micro syringe. The vial was then capped (with a needle) and placed in an aluminum rack within a Parr pressure reactor. Next, the reactor was closed and a CO gas cylinder with a pressure regulator was connected to the reactor. The reactor was flushed with CO gas three times (5 bar; fill and released) and 1 bar of carbon monoxide (measured by pressure meter) was charged. Then 5 bar of N_2 was pressurized to prevent solvent evaporation. The reaction was stirred at 120 °C with a stir rate at 550 rpm for 24 h. After cooling to room temperature, the CO gas was released carefully, and the crude product was purified by silica gel chromatography (PE/EA) to afford the corresponding ester products.

Procedure for Gram Synthesis



Room temperature under air, Na_2CO_3 (530 mg, 5 mmol, 1 equiv), $RhCl_3$ (52.3 mg, 0.25 mmol, 5 mol%), DPPP (309.3 mg, 0.75 mmol, 15 mol%), 4-phenylphenol (0.85 g, 5 mmol, 1 equiv) and NaBr (51.5 mg, 0.5 mmol, 10 mol%) were transferred into an 25-mL round-bottomed flask with a 3.0 cm stirring bar. Then adding dioxane (12.5 mL) with syringe and 1-iodobutane (8 mmol, 910 μL, 1.6 equiv) with micro syringe. The

flask placed in a Parr pressure reactor. Next, the reactor was closed and a CO gas cylinder with a pressure regulator was connected to the reactor. The reactor was flushed with CO gas three times (5 bar; fill and released) and 1 bar of carbon monoxide (measured by pressure meter) was charged. Then 5 bar of N_2 was pressurized to prevent solvent evaporation. The reaction was stirred at 120 °C with a stir rate at 550 rpm for 24 h. After cooling to room temperature, the CO gas was released carefully, and the crude product was purified by silica gel chromatography (PE/EA) to afford the corresponding ester as a white solid (1.27 g, 99% yield).

Preparation of Substrates



***N*-(4-Hydroxyphenyl)acetamide**[1]

To a solution of 4-aminophenol (218.3 mg, 2 mmol) in 3 mL of absolute ethanol was added acetic anhydride (190 µL, 2 mmol). The solution was stirred for 15 min at room temperature, then evaporated to dryness. The resulting solid was purified by silica gel column chromatography (DCM/MeOH = 95:5) and afforded the desired product as a white powder (299.1 mg, 99% yield). **^{1}H NMR** (400 MHz, DMSO-d_6) δ 9.67 (s, 1H), 9.18 (s, 1H), 7.35 (d, *J* = 8.9 Hz, 2H), 6.69 (d, *J* = 8.9 Hz, 2H). **^{13}C NMR** (101 MHz, DMSO-d_6) δ 167.8, 153.3, 131.2, 121.1, 115.2, 23.9.



(2-Iodoethyl)benzene[2]

To a 1 M solution of the corresponding (2-bromoethyl)benzene (238 µL, 2 mmol) in acetone was added NaI (899.3 mg, 6 mmol). The mixture was stirred at 60 °C for 12 h. After cooling to RT, CH_2Cl_2 was added until the complete precipitation of salts. Then, the mixture was washed with a 0.1 M aqueous $Na_2S_2O_3$ solution. The organic phase was collected, dried over $MgSO_4$ and filtered. The mixture was concentrated, then

evaporated to dryness. The resulting solid was purified by silica gel column chromatography (PE) afforded the desired product as a light yellow oil (417.6 mg, 90% yield). **^{1}H NMR** (300 MHz, $CDCl_3$) δ 7.39 - 7.19 (m, 5H), 3.44 - 3.33 (m, 2H), 3.27 - 3.15 (m, 2H). **^{13}C NMR** (75 MHz, $CDCl_3$) δ 140.6, 128.6, 128.3, 126.8, 40.3, 5.5.



(2-Iodoethyl)(phenyl)sulfane[3]

To a solution of 2-(phenylthio)ethan-1-ol (270 µL, 2 mmol) in THF (3.5 ml) was added imidazole (193.4 mg, 2.4 mmol) and triphenylphosphine (629.5 mg, 2.4 mmol) at 0 °C. Then, iodine (609.1, 2.4 mmol) was slowly added to the reaction and the mixture was stirred for 16 h at 25 °C. Next, the mixture was washed with 0.1 M aqueous $Na_2S_2O_3$ solution. The aqueous layer was extracted with EA and the combined organic extracts were dried over $MgSO_4$ and concentrated under vacuum. The compound was purified by column chromatography (PE/EA = 9:1) and afforded the desired product as a light yellow oil (295.8 mg, 96% yield). **^{1}H NMR** (300 MHz, $CDCl_3$) δ 7.37 - 7.14 (m, 5H), 3.42 - 3.08 (m, 4H). **^{13}C NMR** (75 MHz, $CDCl_3$) δ 134.0, 130.6, 129.2, 127.1, 37.0, 2.5.



3-Iodopropyl 4-iodobenzoate[4]

To an oven-dried round bottom flask charged with a mixture of 3-iodopropan-1-ol (0.93 g, 5.0 mmol), Et_3N (0.84 mL, 6.0 mmol) in DCM (10 mL) was added 4-Methoxybenzoyl chloride (0.85 g, 5.0 mmol) at 0°C. The reaction mixture was warmed to room temperature and overnight. The reaction mixture was then partitioned with H_2O (2×10 mL) and brine (15 mL). The organic phase was collected, dried over $MgSO_4$ and filtered. The mixture was concentrated, then evaporated to dryness. The resulting solid was purified by silica gel column chromatography (PE/EA = 10/1) afforded the desired

product as a light yellow oil (1.87 g, 90% yield). **^{1}H NMR** (300 MHz, $CDCl_3$) δ 7.74 (d, *J* = 8.8 Hz, 2H), 7.66 (d, *J* = 8.7 Hz, 2H), 4.33 (t, *J* = 6.1 Hz, 2H), 3.22 (t, *J* = 6.8 Hz, 2H), 2.28 - 2.14 (m, 2H). **^{13}C NMR** (75 MHz, $CDCl_3$) δ 165.9, 137.8, 131.0, 129.4, 100.9, 64.8, 32.4, 1.2.

Mechanistic Studies

Carbonylation of anisole



77 (standard conditions) **78**, not observed

Room temperature under air, Na_2CO_3 (53 mg, 0.5 mmol, 1 equiv), $RhCl_3$ (5.2 mg, 0.025 mmol, 5 mol%), DPPP (30.9 mg, 0.075 mmol, 15 mol%) and NaBr (5.1 mg, 0.05 mmol, 10 mol%) were transferred into an 8-mL vial with a 1.0 cm stirring bar. Then adding dioxane (1.25 mL) with syringe and anisole **77** (54 µL, 0.5 mmol, 1 equiv) with micro syringe. The vial was then capped (with a needle) and placed in an aluminum rack within a Parr pressure reactor. Next, the reactor was closed and a CO gas cylinder with a pressure regulator was connected to the reactor. The reactor was flushed with CO gas three times and 1 bar of carbon monoxide was charged. Then 5 bar of N_2 was pressurized to prevent solvent evaporation. The reaction was stirred at 120 °C with a stirring rate at 550 rpm for 24 h. After cooling to room temperature, the CO gas was released carefully. Then a proper amount of solution was taken for GC-MS analysis, no reaction was observed.

Radical clock experiment



1 **80** **73**, 74% **81**, 15%

Room temperature under air, Na_2CO_3 (53 mg, 0.5 mmol, 1 equiv), $RhCl_3$ (5.2 mg, 0.025 mmol, 5 mol%), DPPP (30.9 mg, 0.075 mmol, 15 mol%), phenol **1** (47.1 mg, 0.5

mmol, 1 equiv) and NaBr (5.1 mg, 0.05 mmol, 10 mol%) were transferred into an 8-mL vial with a 1.0 cm stir bar. Then adding dioxane (1.25 mL) with syringe and (iodomethyl)cyclopropane **80** (75 µL, 0.8 mmol, 1.6 equiv) with micro syringe. The vial was then capped (with a needle) and placed in an aluminum rack within a Parr pressure reactor. Next, the reactor was closed and a CO gas cylinder with a pressure regulator was connected to the reactor. The reactor was flushed with CO gas three times and 1 bar of carbon monoxide was charged. Then 5 bar of N_2 was pressurized to prevent solvent evaporation. The reaction was stirred at 120 °C with a stir rate at 550 rpm for 24 h. After cooling to room temperature, the CO gas was released. The crude product was purified by silica gel chromatography (PE/EA) to afford the products. Then the products analyzed by NMR, the result is shown above.

Competition reaction



Room temperature under air, Na_2CO_3 (53 mg, 0.5 mmol, 1 equiv), $RhCl_3$ (5.2 mg, 0.025 mmol, 5 mol%), DPPP (30.9 mg, 0.075 mmol, 15 mol%), phenol **1** (47.1 mg, 0.5 mmol, 1 equiv) and NaBr (5.1 mg, 0.05 mmol, 10 mol%) were transferred into an 8-mL vial with a 1.0 cm stir bar. Then adding dioxane (1.25 mL) with syringe, 1-iodobutane (91 µL, 0.8 mmol, 1.6 equiv) and 2-iodobutane (92 µL, 0.8 mmol, 1.6 equiv) with micro syringe. The vial was then capped (with a needle) and placed in an aluminum rack within a Parr pressure reactor. Next, the reactor was closed and a CO gas cylinder with a pressure regulator was connected to the reactor. The reactor was flushed with CO gas three times and 1 bar of carbon monoxide was charged. Then 5 bar of N_2 was pressurized to prevent solvent evaporation. The reaction was stirred at 120 °C with a stir rate at 550 rpm for 24 h. After cooling to room temperature, the CO gas was released. The crude product was purified by silica gel chromatography (PE/EA) to afford the products. Then the products analyzed by NMR, the result is shown above.

Radical inhibition experiment



TEMPO	trace
2,6-di-*tert*-butylphenol	99%
α-phenyl styrene	99%

Room temperature under air, Na_2CO_3 (53 mg, 0.5 mmol, 1 equiv), $RhCl_3$ (5.2 mg, 0.025 mmol, 5 mol%), DPPP (30.9 mg, 0.075 mmol, 15 mol%), phenol **1** (47.1 mg, 0.5 mmol, 1 equiv), NaBr (5.1 mg, 0.05 mmol, 10 mol%) and the radical scavenger (1 mmol, 2 equiv) were transferred into an 8-mL vial with a 1.0 cm stirring bar. Then adding dioxane (1.25 mL) with syringe and 1-iodobutane **2** (91 µL, 0.8 mmol, 1.6 equiv) with micro syringe. The vial was then capped (with a needle) and placed in an aluminum rack within a Parr pressure reactor. Next, the reactor was closed and a CO gas cylinder with a pressure regulator was connected to the reactor. The reactor was flushed with CO gas three times and 1 bar of carbon monoxide was charged. Then 5 bar of N_2 was pressurized to prevent solvent evaporation. The reaction was stirred at 120 ℃ with a stir rate at 550 rpm for 24 h. After cooling to room temperature, the CO gas was released. Then a proper amount of solution was taken for GC and GC-MS analysis. The result is shown above.

Characterization of The Products



Phenyl pentanoate (3). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title c ompound as a light yellow oil (86.4 mg, 96% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 7.47 - 7.37 (m, 2H), 7.26 (t, *J* = 7.4 Hz, 1H), 7.13 (d, *J* = 7.4 Hz, 2H), 2.66 - 2.56 (t, 2H), 1.86 - 1.73 (m, 2H), 1.50 (m, *J* = 14.7, 7.4 Hz, 2H), 1.03 (t, *J* = 7.4 Hz, 3H).
^{13}C NMR (101 MHz, $CDCl_3$) δ 172.1, 150.7, 129.3, 125.6, 121.5, 34.0, 26.9, 22.1, 13.6.
HRMS (ESI-TOF): calcd. for $[C_{11}H_{14}O_2+Na]^+$ 201.0891, found 201.0893.



***p*-Tolyl pentanoate (4)**. Prepared according to general procedure using *p*-cresol (54.1 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title c ompound as a light yellow oil (85.2 mg, 97% yield).
^{1}H NMR (300 MHz, $CDCl_3$) δ 7.06 (d, *J* = 8.0 Hz, 2H), 6.86 (d, *J* = 8.3 H z, 2H), 2.50 - 2.33 (t, 2H), 2.24 (s, 3H), 1.73 - 1.56 (m, 2H), 1.35 (m, *J* = 14.5, 7.3 Hz, 2H), 0.88 (t, *J* = 7.3 Hz, 3H).
^{13}C NMR (75 MHz, $CDCl_3$) δ 172.4, 148.5, 135.2, 129.8, 121.1, 34.0, 27.0, 2 2.2, 20.7, 13.6.
HRMS (EI): calcd. for $[C_{12}H_{16}O_2]^+$ 192.1145, found 195.1150.



4-Ethylphenyl pentanoate (5). Prepared according to general procedure using 4 -ethylphenol (61.1 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The cr ude product was purified by silica gel chromatography (PE/EA = 20:1) to affo rd the title compound as a light yellow oil (102 mg, 99% yield).
^{1}H NMR (400 MHz, $CDCl_3$) δ 7.25 (d, *J* = 8.8 Hz, 2H), 7.05 (d, *J* = 8.5 H z, 2H), 2.70 (q, *J* = 7.6 Hz, 2H), 2.64 - 2.56 (m, 2H), 1.86 - 1.73 (m, 2H), 1.51 (m, *J* = 14.7, 7.4 Hz, 2H), 1.29 (t, *J* = 7.6 Hz, 3H), 1.03 (t, *J* = 7.4 H z, 3H).
^{13}C NMR (101 MHz, $CDCl_3$) δ 172.3, 148.6, 141.4, 128.6, 121.2, 121.2, 34.0, 28.2, 26.9, 22.1, 15.4, 13.6.
HRMS (EI): calcd. for $[C_{13}H_{18}O_2]^+$ 206.1301, found 206.1304.



4-(*tert*-Butyl)phenyl pentanoate (6). Prepared according to general procedure u sing 4-*tert*-butylphenol (75.1 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mm ol). The crude product was purified by silica gel chromatography (PE/EA = 20: 1) to afford the title compound as a colorless oil (108.9 mg, 93% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.44 (d, *J* = 9.0 Hz, 2H), 7.06 (d, *J* = 8.9 Hz, 2H), 2.60 (t, 2H), 1.96 - 1.69 (m, 2H), 1.60 - 1.43 (m, 2H), 1.38 (s, 9H), 1.03 (t, *J* = 7.3 Hz, 3H).
^{13}C NMR (75 MHz, $CDCl_3$) δ 172.3, 148.3, 148.3, 126.1, 120.8, 34.3, 34.0, 31.3, 27.0, 22.2, 13.6.
HRMS (EI): calcd. for $[C_{15}H_{22}O_2]^+$ 234.1614, found 234.1612.



4-Methoxyphenyl pentanoate (7). Prepared according to general procedure using 4-methoxyphenol (62.1 mg, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a colorless oil (103 mg, 99% yield).
^{1}H NMR (400 MHz, $CDCl_3$) δ 6.89 (d, *J* = 9.1 Hz, 2H), 6.77 (d, *J* = 9.1 Hz, 2H), 3.67 (s, 3H), 2.47 - 2.38 (t, 2H), 1.69 - 1.57 (m, 2H), 1.34 (m, *J* = 14.7, 7.4 Hz, 2H), 0.87 (t, *J* = 7.4 Hz, 3H).
^{13}C NMR (101 MHz, $CDCl_3$) δ 172.5, 157.0, 144.1, 122.2, 114.2, 55.3, 33.9, 26.9, 22.1, 13.6.
HRMS (EI): calcd. for $[C_{12}H_{16}O_3]^+$ 208.1094, found 208.1096.



[1,1'-Biphenyl]-4-yl pentanoate (8). Prepared according to general procedure using 4-phenylphenol (85.1 mg, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (125.7 mg, 99% yield).
^{1}H NMR (300 MHz, $CDCl_3$) δ 7.49 - 7.40 (m, 4H), 7.30 (t, *J* = 7.3 Hz, 2H), 7.21 (t, 1H), 7.03 (d, 2H), 2.45 (t, 2H), 1.70 - 1.58 (m, 2H), 1.42 - 1.27 (m, 2H), 0.87 (t, *J* = 7.3 Hz, 3H).
^{13}C NMR (75 MHz, $CDCl_3$) δ 172.2, 150.1, 140.3, 138.7, 128.7, 128.0, 127.2, 127.0, 121.7, 34.0, 26.9, 22.2, 13.7.
HRMS (EI): calcd. for $[C_{12}H_{16}O_2]^+$ 254.1301, found 254.1313.



4-(2-Phenylpropan-2-yl)phenyl pentanoate (9). Prepared according to general procedure using 4-(2-phenylpropan-2-yl)phenol (106.2 mg, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (146.6 mg, 99% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 7.17 - 7.07 (m, 6H), 7.04 (t, *J* = 6.6 Hz, 1H), 6.86 (d, *J* = 8.7 Hz, 2H), 2.42 (t, *J* = 7.5 Hz, 2H), 1.61 (dd, *J* = 15.0, 7.7 Hz, 2H), 1.56 (s, 6H), 1.38 - 1.26 (m, 2H), 0.85 (t, *J* = 7.4 Hz, 3H).
^{13}C NMR (101 MHz, $CDCl_3$) δ 172.2, 150.2, 148.5, 147.9, 127.9, 127.9, 127.7, 126.6, 126.6, 126.6, 125.6, 120.7, 42.6, 34.0, 30.7, 26.9, 22.1, 13.6.
HRMS (EI): calcd. for $[C_{20}H_{24}O_2]^+$ 296.1771, found 296.1782.



***m*-Tolyl pentanoate (10)**. Prepared according to general procedure using *m*-cresol (52.3 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (95.1 mg, 99% yield).
^{1}H NMR (300 MHz, $CDCl_3$) δ 7.15 (t, *J* = 7.6 Hz, 1H), 6.93 (d, *J* = 7.7 Hz, 1H), 6.80 (s, 2H), 2.54 - 2.36 (m, 2H), 2.26 (s, 3H), 1.77 - 1.57 (m, 2H), 1.36 (m, *J* = 14.5, 7.3 Hz, 2H), 0.88 (t, *J* = 7.3 Hz, 3H).
^{13}C NMR (101 MHz, $CDCl_3$) δ 172.2, 150.2, 148.5, 147.9, 127.9, 127.9, 127.7, 126.6, 126.6, 126.6, 125.6, 120.7, 42.6, 34.0, 30.7, 26.9, 22.1, 13.6.
HRMS (EI): calcd. for $[C_{12}H_{16}O_2]^+$ 192.1145, found 192.1140.



[1,1'-Biphenyl]-3-yl pentanoate (11). Prepared according to general procedure using 3-(pentyloxy)-1,1'-biphenyl hydrate (85.1 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (125.8 mg, 99% yield).
^{1}H NMR (300 MHz, $CDCl_3$) δ 7.69 - 7.62 (m, 2H), 7.57 - 7.49 (m, 3H), 7.49 - 7.21 (m, 3H), 7.20 - 7.11 (m, 1H), 2.73 - 2.60 (m, 2H), 1.85 (dt, *J* = 15.2, 7.5 Hz, 2H), 1.55 (m, *J* = 14.4, 7.3 Hz, 2H), 1.13 - 1.01 (m, 3H).
^{13}C NMR (75 MHz, $CDCl_3$) δ 172.1, 151.1, 142.7, 140.1, 129.5, 128.7, 127.5, 127.1, 124.4, 121.8, 120.2, 34.0, 26.9, 22.2, 13.7.
HRMS (EI): calcd. for $[C_{17}H_{18}O_2]^+$ 254.1301, found 254.1300.



4-(1*H*-Pyrrol-1-yl)phenyl pentanoate (12). Prepared according to general procedure using 4-(1*H*-pyrrol-1-yl)phenol (79.6 mg, 0.5 mmol) and 1-iodobutane (91

μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light brown oil (120.3 mg, 99% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.44 (d, *J* = 8.7 Hz, 2H), 7.20 (d, *J* = 8.7 Hz, 2H), 7.11 (t, 2H), 6.42 (t, 2H), 2.64 (t, 2H), 1.94 - 1.74 (m, 2H), 1.69 - 1.41 (m, 2H), 1.07 (t, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 172.1, 148.2, 138.3, 122.5, 121.3, 119.3, 110.4, 33.9, 26.8, 22.1, 13.6.

HRMS (ESI-TOF): calcd. for $[C_{15}H_{17}NO_2+H]^+$ 244.1337, found 244.1338.



Naphthalen-2-yl pentanoate (13). Prepared according to general procedure using naphthalen-2-ol (72.8 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (108.5 mg, 95% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 7.95 - 7.84 (m, 3H), 7.66 (s, 1H), 7.60 - 7.46 (m, 2H), 7.32 (d, *J* = 8.8 Hz, 1H), 2.69 (t, *J* = 7.5 Hz, 2H), 1.96 - 1.81 (m, 2H), 1.56 (m, *J* = 14.9, 7.4 Hz, 2H), 1.08 (t, *J* = 7.4 Hz, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 172.3, 148.3, 133.7, 131.3, 129.2, 127.6, 127.5, 126.4, 125.5, 121.1, 118.4, 34.0, 26.9, 22.2, 13.7.

HRMS (EI): calcd. for $[C_{15}H_{16}O_2]^+$ 228.1145, found 228.1152.



Naphthalen-1-yl pentanoate (14). Prepared according to general procedure using naphthalen-1-ol (72.8 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a colorless oil (112.9 mg, 95% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.78 - 7.67 (m, 2H), 7.58 (d, *J* = 8.2 Hz, 1H), 7.41 - 7.26 (m, 3H), 7.12 (d, *J* = 7.5 Hz, 1H), 2.71 - 2.45 (t, 2H), 1.81 - 1.59 (m, 2H), 1.37 (m, *J* = 14.6, 7.3 Hz, 2H), 0.88 (t, *J* = 7.4 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 172.1, 146.6, 134.5, 127.9, 126.8, 126.3, 125.8, 125.3, 121.0, 118.0, 34.0, 27.0, 22.3, 13.7.

HRMS (EI): calcd. for $[C_{15}H_{16}O_2]^+$ 228.1145, found 228.1144.



Anthracen-9-yl pentanoate (15). Prepared according to general procedure using anthracen-9-ol (97.1 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow solid (136.2 mg, 97% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 8.40 (s, 1H), 8.11 - 7.94 (m, 4H), 7.60 - 7.47 (m, 4H), 3.04 - 2.88 (t, 2H), 2.11 - 1.94 (m, 2H), 1.75 - 1.56 (m, 2H), 1.13 (t, *J* = 7.4 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 172.3, 142.1, 131.8, 128.4, 126.1, 125.5, 124.6, 123.9, 121.3, 34.0, 27.3, 22.5, 13.8.

HRMS (EI): calcd. for $[C_{19}H_{18}O_2]^+$ 278.1301, found 278.1301.



4-Fluorophenyl pentanoate (16). Prepared according to general procedure using 4-fluorophenol (56.1 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (97.1 mg, 99% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 6.95 (d, *J* = 1.2 Hz, 2H), 6.94 (s, 2H), 2.48 - 2.41 (t, 2H), 1.69 - 1.59 (m, 2H), 1.41 - 1.28 (m, 2H), 0.87 (t, *J* = 7.4 Hz, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 172.2, 160.1 (d, *J* = 244.0 Hz), 146.5 (d, *J* = 2.9 Hz), 122.9 (d, *J* = 8.5 Hz), 115.9 (d, *J* = 23.5 Hz), 33.9, 26.9, 22.1, 1 3.6.

^{19}F NMR (282 MHz, $CDCl_3$) δ -117.3.

HRMS (EI): calcd. for $[C_{11}H_{13}O_2F_1]^+$ 196.0894, found 196.0893.



4-Cholrophenyl pentanoate (17). Prepared according to general procedure using 4-chlorophenol (64.3 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (105 mg, 99% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 7.35 (d, *J* = 8.8 Hz, 2H), 7.05 (d, *J* = 8.9 H z, 2H), 2.58 (t, 2H), 1.84 - 1.68 (m, 2H), 1.56 - 1.34 (m, 2H), 1.00 (t, *J* = 7. 4 Hz, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 171.9, 149.1, 130.9, 129.3, 122.9, 33.9, 26.8, 22.1, 13.6.

HRMS (EI): calcd. for $[C_{11}H_{13}O_2Cl_1]^+$ 212.0599, found 212.0597.



4-Bromophenyl pentanoate (18). Prepared according to general procedure using 4-bromophenol (86.5 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (126.7 mg, 99% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 7.38 (d, *J* = 8.9 Hz, 2H), 6.88 (d, *J* = 8.9 Hz, 2H), 2.45 (t, 2H), 1.70 - 1.57 (m, 2H), 1.41 - 1.27 (m, 2H), 0.87 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 171.8, 149.7, 132.3, 123.3, 118.6, 33.9, 26.8, 22.1, 13.6.

HRMS (EI): calcd. for $[C_{11}H_{13}O_2Br_1]^+$ 256.0093, found 256.0094.



Methyl 4-(pentanoyloxy)benzoate (19). Prepared according to general procedure using methyl 4-hydroxybenzoate (76.1 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 10:1) to afford the title compound as a colorless oil (116.9 mg, 99% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 8.07 (d, *J* = 8.7 Hz, 2H), 7.16 (d, *J* = 8.7 Hz, 2H), 3.90 (s, 3H), 2.57 (t, *J* = 7.5 Hz, 2H), 1.80 - 1.68 (m, 2H), 1.52 - 1.37 (m, 2H), 0.97 (t, *J* = 7.4 Hz, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 171.5, 166.1, 154.3, 131.0, 127.4, 121.5, 52.0, 34.0, 26.8, 22.1, 13.6.

HRMS (EI): calcd. for $[C_{13}H_{16}O_4]^+$ 236.1043, found 236.1050.



4-Acetylphenyl pentanoate (20). Prepared according to general procedure using 1-(4-hydroxyphenyl)ethan-1-one (68.1 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 10:1) to afford the title compound as a colorless oil (102.3 mg, 93% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.89 (d, *J* = 9.0 Hz, 2H), 7.09 (d, *J* = 8.9 Hz, 2H), 2.49 (m, 5H), 1.72 - 1.59 (m, 2H), 1.44 - 1.29 (m, 2H), 0.88 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 196.7, 171.5, 154.3, 134.5, 129.8, 121.6, 33.9, 26.7, 26.4, 22.1, 13.6.

HRMS (EI): calcd. for $[C_{13}H_{16}O_3]^+$ 220.1094, found 220.1089.



4-Formylphenyl pentanoate (21). Prepared according to general procedure using 4-hydroxybenzaldehyde (61.1 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (100.1 mg, 97% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 9.96 (s, 1H), 7.89 (d, *J* = 8.3 Hz, 2H), 7.25 (d, *J* = 8.9 Hz, 2H), 2.57 (t, *J* = 7.5 Hz, 2H), 1.80 - 1.66 (m, 2H), 1.51 - 1.36 (m, 2H), 0.96 (t, 2H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 190.7, 171.4, 155.3, 133.7, 131.0, 122.2, 33.9, 26.7, 22.0, 13.5.

HRMS (EI): calcd. for $[C_{12}H_{14}O_3]^+$ 206.0938, found 206.0941.



4-Cyanophenyl pentanoate (22). Prepared according to general procedure using 4-hydroxybenzonitrile (59.6 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 5:1) to afford the title compound as a light yellow oil (98.9 mg, 97% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.67 (d, *J* = 8.9 Hz, 2H), 7.22 (d, *J* = 8.9 Hz, 2H), 2.59 (t, 2H), 1.82 - 1.65 (m, 2H), 1.54 - 1.35 (m, 2H), 0.97 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 171.2, 153.9, 133.4, 122.6, 118.1, 109.4, 33.8, 26.6, 22.0, 13.5.

HRMS (EI): calcd. for $[C_{12}H_{13}O_3N_1]^+$ 203.0941, found 203.0944.



4-Nitrophenyl pentanoate (23). Prepared according to general procedure using 4-nitrophenol (69.6 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 5:1) to afford the title compound as a light yellow oil (83.7 mg, 75% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 8.19 (d, *J* = 9.3 Hz, 2H), 7.20 (d, *J* = 9.3 Hz, 2H), 2.53 (t, 2H), 1.86 - 1.57 (m, 2H), 1.52 - 1.22 (m, 2H), 0.90 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 171.3, 155.5, 145.2, 125.2, 122.4, 34.0, 26.8, 22.2, 13.7.

HRMS (EI): calcd. for $[C_{11}H_{13}O_4N_1]^+$ 223.0839, found 223.0843.



***o*-Tolyl pentanoate (24).** Prepared according to general procedure using *o*-cresol (52 µL, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a colorless oil (95,1 mg, 99% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.32 - 7.12 (m, 3H), 7.05 (d, *J* = 7.7 Hz, 1 H), 2.64 (t, 2H), 2.24 (s, 3H), 1.91 - 1.70 (m, 2H), 1.61 - 1.40 (m, 2H), 1.04 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 171.9, 149.3, 131.0, 130.0, 126.8, 125.8, 121.8, 33.9, 27.1, 22.2, 16.1, 13.6.

HRMS (EI): calcd. for $[C_{12}H_{16}O_2]^+$ 192,1145, found 192,1149.



2,4-Dimethylphenyl pentanoate (25). Prepared according to general procedure using 2,4-dimethylphenol (60 µL, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a yellow oil (102 mg, 99% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.10 (s, 1H), 7.07 (d, *J* = 8.1 Hz, 1H), 6.95 (d, *J* = 8.1 Hz, 1H), 2.65 (t, *J* = 7.4 Hz, 2H), 2.37 (s, 3H), 2.21 (s, 3H), 1.9 4 - 1.75 (m, 2H), 1.64 - 1.46 (m, 2H), 1.06 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 172.0, 147.0, 135.3, 131.6, 129.5, 127.3, 121.4, 33.8, 27.0, 22.2, 20.6, 16.0, 13.6.

HRMS (EI): calcd. For $[C_{13}H_{18}O_2]^+$ 206.1301, found 206.1306.



2-Isopropylphenyl pentanoate (26). Prepared according to general procedure using 2-isopropylphenol (67 µL, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (109 mg, 99% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.26 - 7.16 (m, 1H), 7.14 - 7.04 (m, 2H), 6.9 3 - 6.83 (m, 1H), 2.94 (hept, *J* = 6.9 Hz, 1H), 2.54 - 2.43 (t, 2H), 1.77 - 1. 57 (m, 2H), 1.45 - 1.27 (m, 2H), 1.13 (s, 3H), 1.11 (s, 3H), 0.88 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 172.2, 148.1, 140.0, 126.5, 126.1, 122.2, 34.0, 27.2, 27.0, 22.8, 22.2, 13.6.

HRMS (EI): calcd. For $[C_{14}H_{20}O_2]^+$ 220,1458, found 220,1455.



2-(*tert*-Butyl)phenyl pentanoate (27). Prepared according to general procedure using 2-(*tert*-butyl)phenol (77 µL, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a colorless oil (101.3 mg, 87% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.29 (d, *J* = 7.6 Hz, 1H), 7.15 - 7.01 (m, 2 H), 6.89 (d, *J* = 7.7 Hz, 1H), 2.50 (t, *J* = 7.5 Hz, 2H), 1.68 (m, *J* = 15.1, 7. 6 Hz, 2H), 1.37 (m, *J* = 14.5, 7.3 Hz, 2H), 1.26 (s, 9H), 0.89 (t, *J* = 7.4 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 172.2, 149.2, 140.9, 127.1, 126.7, 125.5, 123.9, 34.6, 34.4, 30.1, 26.7, 22.3, 13.7.

HRMS (EI): calcd. For $[C_{15}H_{22}O_2]^+$ 234,1614, found 234,1614.



2-(*tert*-Butyl)-4-methylphenyl pentanoate (28). Prepared according to general procedure using 2-(*tert*-butyl)-4-methylphenol (82.1 mg, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a colorless oil (99.3 mg, 80% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.22 (s, 1H), 7.06 (d, *J* = 8.1 Hz, 1H), 6.90 (d, *J* = 8.1 Hz, 1H), 2.63 (t, 2H), 2.37 (s, 3H), 1.93 - 1.72 (m, 2H), 1.60 - 1.45 (m, 2H), 1.39 (s, 9H), 1.03 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 172.5, 146.9, 140.5, 134.9, 127.8, 127.3, 123.7, 34.7, 34.3, 30.2, 29.5, 26.8, 22.3, 21.1, 13.7.

HRMS (EI): calcd. For $[C_{16}H_{24}O_2]^+$ 248.1771, found 248.1772.



[1,1'-Biphenyl]-2-yl pentanoate (29). Prepared according to general procedure using [1,1'-biphenyl]-2-ol (85.1 mg, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a white solid (125.8 mg, 99% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 7.34 - 7.12 (m, 8H), 7.00 (d, *J* = 8.2 Hz, 1 H), 2.22 (t, *J* = 7.5 Hz, 2H), 1.48 - 1.29 (m, 2H), 1.15 - 1.04 (m, 2H), 0.73 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 172.0, 147.7, 137.5, 134.9, 130.7, 128.9, 128. 3, 128.1, 127.3, 126.1, 122.7, 33.8, 26.6, 21.9, 13.6.

HRMS (EI): calcd. For $[C_{17}H_{18}O_2]^+$ 254.1301, found 254.1305.



2,6-Dimethylphenyl pentanoate (30). Prepared according to general procedure using 2,6-dimethylphenol (61 mg, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica glel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (102 mg, 99% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.19 - 7.09 (m, 3H), 2.68 (t, 2H), 2.23 (s, 6 H), 1.96 - 1.78 (m, 2H), 1.64 - 1.46 (m, 2H), 1.07 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 171.3, 148.1, 130.0, 128.4, 125.6, 33.7, 27.1, 2 2.3, 16.2, 13.6.

HRMS (ESI-TOF): calcd. For $[C_{13}H_{18}O_2+H]^+$ 229.1204, found 229.1207.



[1,1':3',1''-Terphenyl]-2'-yl pentanoate (31). Prepared according to general procedure using [1,1':3',1''-terphenyl]-2'-ol (123.2 mg, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the products as a light yellow oil (162.5 mg, 91% yield and *10% raw materials cannot be separated*).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.68 (d, *J* = 6.9 Hz, 1H), 7.63 - 7.38 (m, 13 H), 2.17 (t, *J* = 7.4 Hz, 2H), 1.46 - 1.26 (m, 2H), 1.20 - 0.97 (m, 2H), 0.85 (t, *J* = 7.2 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 171.4, 149.2, 145.1, 137.8, 137.5, 135.9, 129.9, 129.9, 129.2, 129.0, 128.7, 128.1, 127.5, 127.3, 126.2, 120.6, 33.5, 26.3, 21.7, 13.5.

HRMS (EI): calcd. For $[C_{23}H_{22}O_2]^+$ 330.1614, found 330.1613.



2-Benzoylphenyl pentanoate (32). Prepared according to general procedure using (2-hydroxyphenyl)(phenyl)methanone (99.1 mg, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (133.2 mg, 94% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.79 (d, *J* = 7.0 Hz, 2H), 7.62 - 7.49 (m, 3 H), 7.45 (t, *J* = 7.5 Hz, 2H), 7.38 - 7.27 (m, 1H), 7.21 (d, *J* = 8.6 Hz, 1H), 2.19 (t, 2H), 1.53 - 1.40 (m, 2H), 1.34 - 1.19 (m, 2H), 0.85 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 171.3, 148.1, 130.0, 128.4, 125.6, 33.7, 27.1, 2 2.3, 16.2, 13.6.
HRMS (EI): calcd. For $[C_{18}H_{18}O_3]^+$ 282.1251, found 282.1249.



2-Formylphenyl pentanoate (33). Prepared according to general procedure using 2-hydroxybenzaldehyde (53.3 µL, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a colorless oil (78.7 mg, 76% yield).
^{1}H NMR (400 MHz, $CDCl_3$) δ 10.06 (s, 1H), 7.82 (d, *J* = 7.7, 1.7 Hz, 1H), 7.56 (t, *J* = 8.2, 7.4, 1.8 Hz, 1H), 7.37 - 7.28 (t, 1H), 7.11 (d, *J* = 8.1 Hz, 1 H), 2.65 - 2.55 (t, 2H), 1.71 (m, *J* = 15.1, 7.4 Hz, 2H), 1.40 (m, *J* = 14.7, 7. 4 Hz, 2H), 0.92 (t, *J* = 7.4 Hz, 3H).
^{13}C NMR (75 MHz, $CDCl_3$) δ 188.6, 172.0, 151.8, 135.3, 130.8, 128.1, 126.3, 123.5, 33.9, 26.8, 22.3, 13.7.
HRMS (EI): calcd. For $[C_{12}H_{14}O_3]^+$ 206.0938, found 206.0940.



2-Formyl-6-methylphenyl pentanoate (34). Prepared according to general procedure using 2-hydroxy-3-methylbenzaldehyde (61 µL, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a colorless oil (82.6 mg, 75% yield).
^{1}H NMR (300 MHz, $CDCl_3$) δ 10.06 (s, 1H), 7.72 (d, *J* = 7.6 Hz, 1H), 7.51 (d, *J* = 7.5 Hz, 1H), 7.32 (t, *J* = 7.6 Hz, 1H), 2.77 - 2.66 (m, 2H), 2.24 (s, 3H), 1.89 - 1.76 (m, 2H), 1.58 - 1.43 (m, 2H), 1.01 (t, *J* = 7.3 Hz, 3H).
^{13}C NMR (75 MHz, $CDCl_3$) δ 189.0, 171.7, 150.1, 136.9, 132.0, 129.2, 128.2, 126.1, 33.6, 26.8, 22.3, 15.8, 13.7.
HRMS (EI): calcd. For $[C_{13}H_{16}O_3]^+$ 220.1094, found 220.1090.



2-Allylphenyl pentanoate (35). Prepared according to general procedure using 2-allylphenol (26 µL, 0.2 mmol) and 1-iodobutane (36 µL, 0.32 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a colorless oil (43.2 mg, 99% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.20 - 7.02 (m, 3H), 6.97 - 6.86 (m, 1H), 6.01 - 5.62 (m, 1H), 5.04 - 4.80 (m, 2H), 3.21 (d, *J* = 6.6 Hz, 2H), 2.49 (t, 2H), 1.73 - 1.60 (m, 2H), 1.37 (m, *J* = 14.5, 7.3 Hz, 2H), 0.89 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 189.0, 171.7, 150.1, 136.9, 132.0, 129.2, 128.2, 126.1, 33.6, 26.8, 22.3, 15.8, 13.7.

HRMS (ESI-TOF): calcd. For $[C_{14}H_{18}O_2+H]^+$ 219.1385, found 219.1390.



2-Cyanophenyl pentanoate (36). Prepared according to general procedure using 2-hydroxybenzonitrile (59.6 mg, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 5:1) to afford the title compound as a colorless oil (78.2 mg, 77% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 7.63 - 7.48 (m, 2H), 7.25 (t, *J* = 7.7 Hz, 1H), 7.20 (d, *J* = 8.3 Hz, 1H), 2.82 - 2.34 (t, 2H), 1.71 (m, *J* = 15.2, 7.5 Hz, 2H), 1.46 - 1.20 (m, 2H), 0.90 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 171.2, 152.4, 133.9, 133.2, 126.1, 123.2, 115.1, 107.1, 33.8, 26.7, 22.1, 13.6.

HRMS (EI): calcd. For $[C_{12}H_{13}O_2N_1]^+$ 203.0941, found 203.0938



2-Acetylphenyl pentanoate (37). Prepared according to general procedure using 1-(2-hydroxyphenyl)ethan-1-one (69 µL, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 10:1) to afford the title compound as a light yellow oil (77.9 mg, 71% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 7.80 (d, *J* = 6.2 Hz, 1H), 7.53 (t, 1H), 7.31 (t, 1H), 7.11 (d, *J* = 8.1 Hz, 1H), 2.68 - 2.59 (m, 2H), 2.56 (s, 3H), 1.82 - 1.72 (m, 2H), 1.53 - 1.41 (m, 2H), 0.99 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 197.6, 172.1, 149.0, 133.2, 130.9, 130.1, 125.8, 125.8, 123.7, 34.0, 29.4, 26.5, 22.2, 13.7.

HRMS (EI): calcd. For $[C_{13}H_{16}O_3]^+$ 220.1094, found 220.1093.



2-Bromo-4,5-difluorophenyl pentanoate (38). Prepared according to general procedure using 2-bromo-4,5-difluorophenol (57 µL, 0.5 mmol) and 1-iodobutane (91

μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (140 mg, 96% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 7.35 (dd, *J* = 9.4, 8.0 Hz, 1H), 6.94 (dd, *J* = 10.2, 7.2 Hz, 1H), 2.57 - 2.41 (m, 2H), 1.76 - 1.61 (m, 2H), 1.43 - 1.32 (m, 2H), 0.89 (t, *J* = 7.4 Hz, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 170.9, 150.6, 150.5, 149.31 (dd, *J* = 251.5, 13.7 Hz), 148.10 (dd, *J* = 251.3, 13.4 Hz), 146.9, 146.8, 144.25 (dd, *J* = 8.4, 3.7 Hz), 121.19 (d, *J* = 21.1 Hz), 113.13 (d, *J* = 20.5 Hz), 110.28 (dd, *J* = 7.5, 4.2 Hz), 33.7, 26.8, 22.2, 13.7.

^{19}F NMR (282 MHz, $CDCl_3$) δ -134.97, -135.05, -137.87, -137.94.

HRMS (EI): calcd. For $[C_{11}H_{11}O_2Br_1F_2]^+$ 291.9905, found 291.9912.



2,6-Dibromo-4-fluorophenyl pentanoate (39). Prepared according to general procedure using 2,6-dibromo-4-fluorophenol (135 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (117.9 mg, 67% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 7.24 (d, *J* = 7.5 Hz, 2H), 2.72 - 2.47 (t, 2H), 1.78 - 1.62 (m, 2H), 1.52 - 1.30 (m, 2H), 0.90 (t, *J* = 7.4 Hz, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 170.0, 159.40 (d, *J* = 252.9 Hz), 124.43 (d, *J* = 8.9 Hz), 119.68 (d, *J* = 25.6 Hz), 117.79 (d, *J* = 10.7 Hz), 33.6, 26.8, 22.3, 13.7.

^{19}F NMR (282 MHz, $CDCl_3$) δ -112.98.

HRMS (EI): calcd. For $[C_{11}H_{11}O_2Br_2F_1]^+$ 351.9104, found 351.9101.



[1,1'-Biphenyl]-2,2'-diyl dipentanoate (40). Prepared according to general procedure using [1,1'-biphenyl]-2,2'-diol (46.6 mg, 0.25 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a colorless oil (79.2 mg, 90% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.4 (m, *J* = 8.0, 6.4, 2.7 Hz, 2H), 7.4 - 7.2 (m, 4H), 7.2 (d, *J* = 7.9 Hz, 2H), 2.5 - 2.1 (t, 4H), 1.6 - 1.4 (m, 4H), 1.2 (m, *J* = 14.8, 14.3, 7.4 Hz, 4H), 1.0 - 0.8 (t, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 171.9, 148.2, 131.1, 130.6, 128.8, 125.7, 122.4, 33.7, 26.7, 21.9, 13.6.

HRMS (EI): calcd. For $[C_{22}H_{26}O_4]^+$ 354.1826, found 354.1835.



1,4-Phenylene dipentanoate (41). Prepared according to general procedure using hydroquinone (27.5 mg, 0.25 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a colorless solid (67.6 mg, 97% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.00 (s, 4H), 2.54 - 2.36 (m, 4H), 1.77 - 1.55 (m, 4H), 1.36 (m, *J* = 14.5, 7.3 Hz, 4H), 0.89 (t, *J* = 7.3 Hz, 6H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 172.1, 148.1, 122.4, 34.1, 27.0, 22.2, 13.7.

HRMS (EI): calcd. For $[C_{16}H_{22}O_4]^+$ 278.1513, found 278.1510.



[1,1'-Binaphthalene]-2,2'-diyl dipentanoate (42). Prepared according to general procedure using [1,1'-binaphthalene]-2,2'-diol (71.6 mg, 0.25 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (112.4 mg, 99% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.88 (d, *J* = 8.7 Hz, 2H), 7.81 (d, *J* = 8.2 Hz, 2H), 7.39 - 7.28 (m, 4H), 7.24 - 7.10 (m, 4H), 1.99 (td, *J* = 7.4, 1.5 Hz, 4H), 1.07 - 0.94 (m, 4H), 0.87 - 0.73 (m, 4H), 0.53 (t, *J* = 7.2 Hz, 6H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 171.9, 146.9, 133.4, 131.6, 129.4, 128.0, 126.7, 126.2, 125.7, 123.7, 122.0, 33.8, 26.6, 21.8, 13.6.

HRMS (EI): calcd. For $[C_{30}H_{30}O_4]^+$ 454.2139, found 454.2141.



9*H*-Carbazol-2-yl pentanoate (43). Prepared according to general procedure using 9*H*-carbazol-2-ol (91.6 mg, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 10:1) to afford the title compound as a light yellow solid (109.9 mg, 82% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 8.15 (s, 1H), 7.92 (d, *J* = 7.8 Hz, 1H), 7.88 (d, *J* = 8.4 Hz, 1H), 7.42 - 7.33 (m, 1H), 7.28 - 7.17 (m, 2H), 7.00 (d, *J* = 1.7 Hz, 1H), 6.93 (dd, *J* = 8.4, 2.1 Hz, 1H), 2.77 - 2.63 (m, 2H), 1.95 - 1.83 (m, 2H), 1.65 - 1.50 (m, 2H), 1.10 (t, *J* = 7.4 Hz, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 173.4, 149.0, 140.1, 139.9, 125.5, 122.7, 121.1, 120.7, 120.0, 119.4, 113.0, 110.8, 103.9, 34.3, 27.2, 22.4, 13.9.

HRMS (ESI-TOF): calcd. For $[C_{17}H_{17}NO_2+H]^+$ 290.1156, found 290.1158.



1*H*-Indol-5-yl pentanoate (44). Prepared according to general procedure using 1*H*-indol-5-ol (66.6 mg, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 10:1) to afford the title compound as a colorless solid (107.5 mg, 99% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 8.38 (s, 1H), 7.40 (dd, *J* = 2.3, 0.7 Hz, 1H), 7.16 (d, *J* = 8.7 Hz, 1H), 7.03 (t, *J* = 2.8 Hz, 1H), 6.92 (dd, *J* = 8.7, 2.3 H z, 1H), 6.62 - 6.40 (m, 1H), 2.69 (t, *J* = 7.5 Hz, 2H), 1.88 (p, *J* = 7.7 Hz, 2 H), 1.67 - 1.47 (m, 2H), 1.08 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 173.7, 144.0, 133.5, 127.9, 125.7, 115.6, 112.2, 111.5, 102.1, 34.1, 27.0, 22.2, 13.6.

HRMS (EI): calcd. For $[C_{13}H_{15}NO_2]^+$ 217.1097, found 217.1097.



4-Acetamidophenyl pentanoate (45). Prepared according to general procedure using *N*-(4-hydroxyphenyl)acetamide (76 mg, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 5:1) to afford the title compound as a brown solid (116.3 mg, 99% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 8.45 (s, 1H), 7.42 (d, *J* = 8.9 Hz, 2H), 6.92 (d, *J* = 8.9 Hz, 2H), 2.53 (t, *J* = 7.5 Hz, 2H), 2.04 (s, 3H), 1.77 - 1.65 (m, 2H), 1.42 (m, *J* = 14.7, 7.4 Hz, 2H), 0.94 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 172.8, 169.0, 146.5, 135.8, 121.6, 120.9, 33.9, 26.8, 24.0, 22.1, 13.6.

HRMS (ESI-TOF): calcd. For $[C_{13}H_{17}NO_3+H]^+$ 236.1286, found 236.1284.



4-(Hydroxymethyl)phenyl pentanoate (46). Prepared according to general procedure using 4-(hydroxymethyl)phenol (62.1 mg, 0.5 mmol) and 1-iodobutane (91 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 10:1) to afford the title compound as a light brown oil (82 mg, 80% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.33 (d, *J* = 8.8 Hz, 2H), 7.05 (d, *J* = 8.7 H z, 2H), 4.60 (s, 2H), 2.57 (m, 3H), 1.84 - 1.65 (m, 2H), 1.56 - 1.34 (m, 2H), 0.99 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 172.4, 149.9, 138.4, 127.9, 121.5, 64.3, 34.0, 2 6.9, 22.1, 13.6.

HRMS (EI): calcd. For $[C_{12}H_{16}O_3]^+$ 208.1094, found 208.1010.



4-Iodophenyl pentanoate (47). Prepared according to general procedure using 4-iodophenol (110 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (93.3 mg, 61% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 7.59 (d, *J* = 8.9 Hz, 2H), 6.77 (d, *J* = 8.9 Hz, 2H), 2.50 - 2.39 (m, 2H), 1.71 - 1.57 (m, 2H), 1.42 - 1.28 (m, 2H), 0.88 (t, *J* = 7.4 Hz, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 171.8, 150.5, 138.3, 123.7, 89.6, 34.0, 26.8, 22.2, 13.7.

HRMS (EI): calcd. For $[C_{11}H_{13}O_2I]^+$ 303.9955, found 303.9958.



2-Iodophenyl pentanoate (48). Prepared according to general procedure using 2-iodophenol (110 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (145.6 mg, 96% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 7.72 (d, *J* = 6.4 Hz, 1H), 7.25 (t, 1H), 6.99 (d, *J* = 6.6 Hz, 1H), 6.86 (t, 1H), 2.54 (t, 2H), 1.76 - 1.64 (m, 2H), 1.46 - 1.32 (m, 2H), 0.89 (t, *J* = 7.4 Hz, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 171.4, 151.2, 139.4, 129.4, 127.5, 123.1, 90.6, 34.2, 26.9, 22.4, 13.8.

HRMS (EI): calcd. For $[C_{11}H_{13}O_2I]^+$ 303.9955, found 303.9960.



2,5-Dimethyl-4-oxo-4,5-dihydrofuran-3-yl pentanoate (49). Prepared according to general procedure using *Furaneol* (64.1 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (80.1 mg, 76% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 4.49 (q, *J* = 7.3 Hz, 1H), 2.46 (t, 2H), 2.08 (s, 3H), 1.69 - 1.56 (m, 2H), 1.42 (d, *J* = 7.2 Hz, 3H), 1.39 - 1.27 (m, 2H), 0.87 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 195.7, 179.8, 170.4, 128.9, 81.2, 33.1, 26.7, 22.0, 16.2, 13.9, 13.5.

HRMS (EI): calcd. For $[C_{11}H_{16}O_4]^+$ 212.1043, found 212.1043.



Benzo[*d*][1,3]dioxol-5-yl pentanoate (50). Prepared according to general procedure using *Sesamol* (69.1 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a yellow oil (109.9 mg, 99% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 6.67 (d, *J* = 8.4 Hz, 1H), 6.50 (d, *J* = 2.0 Hz, 1H), 6.42 (dd, *J* = 8.4, 2.3 Hz, 1H), 5.86 (m, 2H), 2.49 - 2.35 (t, 2H), 1.71 - 1.54 (m, 2H), 1.34 (m, *J* = 14.5, 7.4 Hz, 2H), 0.94 - 0.76 (t, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 172.4, 147.9, 145.1, 145.0, 113.8, 107.8, 103.6, 101.6, 33.9, 26.9, 22.1, 13.6.

HRMS (EI): calcd. For $[C_{12}H_{14}O_4]^+$ 222.0887, found 222.0882.



(8*R*,9*S*,13*S*,14*S*)-13-Methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl pentanoate (51). Prepared according to general procedure using *Estrone* (135.2 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a white solid (169.4 mg, 96% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.28 (d, *J* = 8.4 Hz, 1H), 6.84 (d, *J* = 8.4 Hz, 1H), 6.81 (s, 1H), 2.91 (dd, *J* = 8.0, 3.4 Hz, 2H), 2.60 - 2.34 (m, 4H), 2.35 - 1.90 (m, 5H), 1.80 - 1.36 (m, 10H), 0.97 (t, *J* = 7.3 Hz, 3H), 0.91 (s, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 220.5, 172.4, 148.5, 137.8, 137.1, 126.2, 121.4, 118.6, 50.2, 47.8, 44.0, 37.8, 35.7, 33.9, 31.4, 29.2, 26.9, 26.2, 25.6, 22.1, 21.4, 13.7, 13.6.

HRMS (EI): calcd. For $[C_{23}H_{30}O_3]^+$ 354.2190, found 354.2182.



(*R*)-2,5,7,8-Tetramethyl-2-((4*R*,8*R*)-4,8,12-trimethyltridecyl)chroman-6-yl pentanoate (52). Prepared according to general procedure using *Vitamin E* (215.4 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a yellow oil (235.8 mg, 92% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 2.64 (dd, *J* = 8.1, 7.2 Hz, 4H), 2.14 (s, 3H), 2.06 (s, 3H), 2.02 (s, 3H), 1.93 - 1.73 (m, 4H), 1.67 - 1.10 (m, 27H), 1.03 (t, *J* = 7.3 Hz, 3H), 0.96 - 0.84 (m, 12H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 172.22, 149.26, 140.47, 126.61, 124.81, 122.90, 117.22, 74.90, 39.33, 37.48, 37.42, 37.35, 37.25, 33.80, 32.72, 32.64, 31.03, 27.93, 27.18, 24.78, 24.76, 24.40, 22.67, 22.58, 22.41, 20.98, 20.55, 19.70, 19.63, 19.54, 13.69, 12.88, 12.03, 11.76.

HRMS (EI): calcd. For $[C_{34}H_{58}O_3]^+$ 514.4381, found 514.4379.



4-((2*S*,3*R*)-1-(4-Fluorophenyl)-3-((*S*)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-oxoazetidin-2-yl)phenyl pentanoate (53). Prepared according to general procedure using *Ezetimibe* (204.7 mg, 0.5 mmol) and 1-iodobutane (91 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 10:1) to afford the title compound as a brown solid (149 mg, 61% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.39 - 7.17 (m, 6H), 7.11 (d, *J* = 8.6 Hz, 2H), 6.96 (dt, *J* = 20.9, 8.6 Hz, 4H), 4.90 - 4.52 (m, 2H), 3.13 - 2.94 (m, 1H), 2.57 (t, *J* = 7.5 Hz, 2H), 2.40 - 2.13 (m, 1H), 2.06 - 1.84 (m, 4H), 1.75 (p, *J* = 7.4 Hz, 2H), 1.46 (dp, *J* = 14.6, 7.3 Hz, 2H), 0.98 (t, *J* = 7.3 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 172.02, 167.32, 163.49, 160.44, 160.24, 157.21, 150.66, 140.04, 140.01, 134.69, 133.50, 133.47, 127.27, 127.17, 126.70, 122.29, 118.27, 118.17, 115.83, 115.53, 115.16, 114.88, 72.65, 60.59, 60.11, 36.37, 33.83, 26.72, 24.77, 22.00, 13.51.

^{19}F NMR (282 MHz, $CDCl_3$) δ -114.99, -117.62.

HRMS (ESI-TOF): calcd. For $[C_{29}H_{29}NO_4F_2+H]^+$ 494.2143, found 494.2148.



[1,1'-Biphenyl]-4-yl acetate (54). Prepared according to general procedure using [1,1'-biphenyl]-4-ol (85.1 mg, 0.5 mmol) and iodomethane (50 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a white solid (103.9 mg, 97% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.48 - 7.41 (m, 4H), 7.30 (t, *J* = 7.3 Hz, 2H), 7.21 (t, 1H), 7.03 (d, *J* = 8.9 Hz, 2H), 2.17 (s, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 169.4, 150.0, 140.2, 138.8, 128.7, 128.0, 127.2, 127.0, 121.7, 21.0.

HRMS (EI): calcd. For $[C_{14}H_{12}O_2]^+$ 212.0832, found 212.0834.



Phenyl propionate (55). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and iodoethane (64 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (72.9 mg, 99% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.42 (t, 2H), 7.26 (t, 1H), 7.13 (d, *J* = 7.4 Hz, 2H), 2.63 (q, *J* = 7.5 Hz, 2H), 1.31 (t, *J* = 7.6 Hz, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 172.8, 150.7, 129.3, 125.6, 121.5, 77.4, 77.0, 76.6, 27.7, 9.0.

HRMS (EI): calcd. For $[C_9H_{10}O_2]^+$ 150.0675, found 150.0676.



Phenyl nonanoate (56). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and 1-iodooctane (144 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (115.9 mg, 99% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.48 - 7.36 (m, 2H), 7.32 - 7.20 (m, 1H), 7.14 (d, *J* = 7.4 Hz, 2H), 2.66 - 2.53 (t, 2H), 1.81 (m, *J* = 7.2 Hz, 2H), 1.60 - 1.29 (m, 11H), 1.06 - 0.90 (t, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 172.1, 150.7, 129.2, 125.5, 121.5, 77.4, 77.0, 76.6, 34.3, 31.7, 29.1, 29.0, 29.0, 24.8, 22.5, 14.0.

HRMS (EI): calcd. For $[C_{15}H_{22}O_2]^+$ 234.1614, found 234.1625.



Phenyl nonadecanoate (57). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and 1-iodooctadecane (304 mg, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a white solid (185.3 mg, 99% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.42 (t, 2H), 7.26 (t, 1H), 7.13 (d, *J* = 7.4 Hz, 2H), 2.60 (t, *J* = 7.5 Hz, 2H), 1.92 - 1.70 (m, 2H), 1.34 (m, 30H), 1.02 - 0.90 (t, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 172.1, 150.7, 129.2, 125.5, 121.5, 34.3, 31.9, 29.7, 29.6, 29.6, 29.4, 29.3, 29.2, 29.1, 24.9, 22.7, 14.1.

HRMS (EI): calcd. For $[C_{25}H_{42}O_2]^+$ 374.3179, found 374.3174.



Phenyl 3-phenylpropanoate (58). Prepared according to general procedure usin g phenol (18.8 mg, 0.2 mmol) and (2-iodoethyl)benzene (74.3 mg, 0.32 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a colorless oil (43.5 mg, 96% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.47 - 7.23 (m, 9H), 7.13 - 7.03 (m, 2H), 3.1 5 (t, *J* = 7.6 Hz, 2H), 2.95 (t, 2H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 171.3, 150.6, 140.1, 129.3, 128.5, 128.3, 126.4, 125.7, 121.5, 35.9, 30.9.

HRMS (EI): calcd. For $[C_{15}H_{14}O_2]^+$ 226.0988, found 226.0990.



Phenyl 3-phenylpropanoate (59). Prepared according to general procedure usin g phenol (18.8 mg, 0.2 mmol) and (3-iodopropane-1,1-diyl)dibenzene (103 mg, 0.32 mmol). The crude product was purified by silica gel chromatography (PE/ EA = 20:1) to afford the title compound as a colorless oil (49.6 mg, 78% yiel d).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.52 - 7.21 (m, 13H), 7.12 (d, *J* = 7.4 Hz, 2 H), 4.18 - 4.05 (m, 1H), 2.68 - 2.50 (m, 4H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 171.8, 150.6, 143.9, 129.3, 128.6, 127.8, 126.4, 125.7, 121.5, 50.4, 32.8, 30.5.

HRMS (EI): calcd. For $[C_{22}H_{20}O_2]^+$ 316.1458, found 316.1460.



Phenyl cyclopentanecarboxylate (60). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and iodocyclopentane (93 µL, 0.8 mmol). T he crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (43,7 mg, 46% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.36 - 7.24 (m, 2H), 7.20 - 7.08 (m, 1H), 7.0 0 (d, *J* = 7.4 Hz, 2H), 3.00 - 2.83 (m, 1H), 2.01 - 1.47 (m, 9H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 175.2, 150.9, 129.3, 125.6, 121.5, 43.9, 30.1, 2 5.9.

HRMS (EI): calcd. For $[C_{12}H_{14}O_2]^+$ 190,0988, found 192,0992.



Phenyl 5,5,5-trifluoropentanoate (61). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and 1,1,1-trifluoro-4-iodobutane (103 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a colorless oil (114.9 mg, 99% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.3 - 7.2 (t, 2H), 7.2 - 7.1 (t, 1H), 7.0 (d, *J* = 7.4 Hz, 2H), 2.5 (t, *J* = 7.3 Hz, 2H), 2.2 - 2.0 (m, 2H), 2.0 - 1.8 (m, 2H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 170.9, 150.5, 129.4, 125.8, 121.4, 33.3, 32.9, 32.7, 32.5, 32.1, 17.3 (q, *J* = 3.3 Hz).

^{19}F NMR (282 MHz, $CDCl_3$) δ -66.26.

HRMS (EI): calcd. For $[C_{11}H_{11}O_2F_3]^+$ 232.0706, found 232.0702.



Phenyl 3-(phenylthio)propanoate (62). Prepared according to general procedure using phenol (18.8 mg, 0.2 mmol) and (2-iodoethyl)(phenyl)sulfane (84.5 mg, 0.32 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (127.7 mg, 99% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.58 - 7.31 (m, 6H), 7.35 - 7.22 (m, 2H), 7.20 - 7.08 (m, 2H), 3.33 (t, *J* = 7.4 Hz, 2H), 2.92 (t, *J* = 7.4 Hz, 2H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 170.2, 150.5, 134.9, 130.4, 129.4, 129.1, 126.7, 125.8, 121.4, 34.5, 29.2.

HRMS (ESI-TOF): calcd. For $[C_{15}H_{14}O_2S+H]^+$ 259.0793, found 259.0790.



Phenyl 6-iodohexanoate (63). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and 1,5-diiodopentane (119 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a colorless oil (61 mg, 38% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.36 - 7.22 (m, 2H), 7.20 - 7.08 (m, 1H), 7.00 (d, *J* = 7.4 Hz, 2H), 3.13 (t, *J* = 6.9 Hz, 2H), 2.50 (t, *J* = 7.4 Hz, 2H), 1.88 - 1.62 (m, 4H), 1.54 - 1.35 (m, 2H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 171.9, 150.7, 129.4, 125.8, 121.6, 34.1, 33.1, 29.9, 23.9, 6.6.

HRMS (ESI-TOF): calcd. For $[C_{12}H_{15}O_2I+H]^+$ 319.0195, found 319.0201.



4-Oxo-4-phenoxybutyl 4-iodobenzoate (64). Prepared according to general proc edure using phenol (18.8 mg, 0.2 mmol) and 3-iodopropyl 4-iodobenzoate (133. 1 mg, 0.32 mmol). The crude product was purified by silica gel chromatograp hy (PE/EA = 20:1) to afford the title compound as a yellow oil (61 mg, 38% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.87 - 7.69 (m, 4H), 7.43 - 7.30 (m, 2H), 7.2 9 - 7.17 (m, 1H), 7.06 (d, *J* = 7.4 Hz, 2H), 4.44 (t, *J* = 6.3 Hz, 2H), 2.74 (t, *J* = 7.3 Hz, 2H), 2.33 - 2.16 (m, 2H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 171.3, 166.0, 150.6, 137.8, 131.1, 129.5, 129.4, 125.9, 121.5, 100.9, 64.1, 31.1, 24.1.

HRMS (ESI-TOF): calcd. For $[C_{17}H_{15}O_4I+H]^+$ 411.0093, found 411.0098.



Phenyl 2-phenylacetate (65). Prepared according to general procedure using ph enol (47.1 mg, 0.5 mmol) and (bromomethyl)benzene (95 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to aff ord the title compound as a light yellow oil (105 mg, 99% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.56 - 7.40 (m, 1H), 7.31 (t, *J* = 7.4 Hz, 0H), 7.19 (d, *J* = 8.6 Hz, 0H), 3.96 (s, 1H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 150.6, 133.4, 129.2, 129.2, 128.6, 127.2, 125.7, 121.3, 41.2.

HRMS (EI): calcd. For $[C_{14}H_{12}O_2]^+$ 212.0832, found 212.0830.



Phenyl heptanoate (66). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and 1-bromohexane (112 µL, 0.8 mmol). The crude prod uct was purified by silica gel chromatography (PE/EA = 20:1) to afford the tit le compound as a colorless oil (102 mg, 99% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 7.42 (t, 2H), 7.26 (t, *J* = 7.4 Hz, 1H), 7.13 (d, *J* = 7.4 Hz, 2H), 2.60 (t, 2H), 1.96 - 1.65 (m, 2H), 1.58 - 1.21 (m, 6H), 0.98 (t, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 172.1, 150.7, 129.2, 125.5, 121.5, 34.3, 31.4, 28.7, 24.8, 22.4, 13.9.

HRMS (EI): calcd. For $[C_{13}H_{18}O_2]^+$ 206.1301, found 206.1301.



Phenyl 5-methylhexanoate (67). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and 1-bromo-4-methylpentane (117 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a colorless oil (91.1 mg, 88% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 7.44 - 7.34 (t, 2H), 7.26 (t, *J* = 7.4 Hz, 1H), 7.12 (d, *J* = 7.5 Hz, 2H), 2.58 (t, *J* = 7.5 Hz, 2H), 1.88 - 1.74 (m, 2H), 1.65 (m, *J* = 13.3, 6.7 Hz, 1H), 1.40 - 1.25 (m, 2H), 0.98 (s, 3H), 0.96 (s, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 172.2, 150.7, 129.3, 125.6, 121.5, 38.3, 34.5, 27.7, 22.8, 22.4.

HRMS (EI): calcd. For $[C_{13}H_{18}O_2]^+$ 206.1301, found 206.1305.



Phenyl 3-cyclohexylpropanoate (68). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and (2-bromoethyl)cyclohexane (125 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a colorless oil (92.9 mg, 80% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 7.28 (t, 2H), 7.12 (t, *J* = 7.4 Hz, 1H), 6.99 (d, *J* = 7.5 Hz, 2H), 2.47 (t, 2H), 1.73 - 1.52 (m, 7H), 1.28 - 1.02 (m, 4H), 0.95 - 0.78 (m, 2H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 172.5, 150.7, 129.3, 125.6, 121.5, 37.2, 32.9, 32.3, 32.0, 26.5, 26.2.

HRMS (EI): calcd. For $[C_{15}H_{20}O_2]^+$ 232.1458, found 232.1461.



Phenyl 4,8-dimethylnonanoate (69). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and 1-bromo-3,7-dimethyloctane (166 μL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a colorless oil (98.8 mg, 75% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.33 - 7.22 (m, 2H), 7.18 - 7.06 (m, 1H), 6.99 (d, *J* = 7.4 Hz, 2H), 2.57 - 2.40 (m, 2H), 1.85 - 1.65 (m, 1H), 1.57 - 1.39 (m, 3H), 1.30 - 1.16 (m, 4H), 1.14 - 1.01 (m, 4H), 0.85 (d, *J* = 6.4 Hz, 3H), 0.81 (s, 3H), 0.78 (s, 3H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 172.4, 150.7, 129.3, 125.6, 121.5, 39.2, 36.9, 32.4, 32.2, 31.8, 27.9, 24.6, 22.6, 22.6, 19.3.

HRMS (ESI-TOF): calcd. For $[C_{17}H_{26}O_2+H]^+$ 263.2011, found 263.2018.



Phenyl 5-(1,3-dioxoisoindolin-2-yl)pentanoate (70). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and 2-(4-bromobutyl)isoindoline-1,3-dione (225.7 mg, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a colorless solid (128.9 mg, 80% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 7.82 (dd, *J* = 5.5, 3.0 Hz, 2H), 7.68 (dd, *J* = 5.4, 3.1 Hz, 2H), 7.35 (t, *J* = 8.0 Hz, 2H), 7.20 (t, *J* = 7.4 Hz, 1H), 7.07 (d, *J* = 7.5 Hz, 2H), 3.74 (t, *J* = 6.7 Hz, 2H), 2.62 (t, *J* = 7.0 Hz, 2H), 1.87 - 1.74 (m, 4H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 171.4, 168.1, 150.5, 133.7, 131.8, 129.2, 125.5, 123.0, 121.4, 37.2, 33.5, 27.7, 21.9.

HRMS (ESI-TOF): calcd. For $[C_{19}H_{17}NO_4+H]^+$ 346.1055, found 346.1053.



Phenyl 5-cyanopentanoate (71). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and 5-bromopentanenitrile (93 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a yellow oil (85.1 mg, 84% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.40 (t, 2H), 7.25 (t, 1H), 7.10 (d, *J* = 7.4 Hz, 2H), 2.62 (t, *J* = 7.2 Hz, 2H), 2.39 (t, 2H), 1.96 - 1.85 (m, 2H), 1.84 - 1.72 (m, 2H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 171.1, 150.4, 129.3, 125.7, 121.3, 119.2, 33.1, 24.6, 23.6, 16.8.

HRMS (ESI-TOF): calcd. For $[C_{12}H_{13}NO_2+H]^+$ 226.0843, found 226.0842.



Phenyl but-3-enoate (72). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and 3-bromoprop-1-ene (69 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (56.9 mg, 70% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.37 - 7.25 (t, 2H), 7.22 - 7.09 (t, 2H), 7.02 (d, *J* = 7.5 Hz, 2H), 6.06 - 5.83 (m, 1H), 5.30 - 5.11 (m, 2H), 3.27 (dt, *J* = 6.9, 1.5 Hz, 2H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 169.9, 150.6, 129.6, 129.4, 125.8, 121.5, 119.2, 39.1.

HRMS (EI): calcd. For $[C_{10}H_{10}O_2]^+$ 16.0675, found 162.0675.



Phenyl pent-4-enoate (73). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and 4-bromobut-1-ene (81 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (80.1 mg, 91% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.42 (t, 2H), 7.26 (t, 1H), 7.13 (d, *J* = 7.4 Hz, 2H), 6.07 - 5.82 (m, 1H), 5.34 - 5.00 (m, 2H), 2.71 (t, 2H), 2.62 - 2.49 (m, 2H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 169.9, 150.6, 129.6, 129.4, 125.8, 121.5, 119.2, 39.1.

HRMS (EI): calcd. For $[C_{11}H_{12}O_2]^+$ 176.0832, found 176.0831.



Phenyl hex-5-enoate (74). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and 5-bromopent-1-ene (95 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (82.7 mg, 87% yield).

^{1}H NMR (400 MHz, $CDCl_3$) δ 7.47 - 7.37 (m, 1H), 7.26 (t, *J* = 7.5 Hz, 1H), 7.13 (d, *J* = 7.5 Hz, 1H), 5.88 (td, *J* = 16.9, 6.7 Hz, 1H), 5.18 - 5.05 (m, 1H), 2.62 (t, *J* = 7.5 Hz, 2H), 2.29 - 2.18 (m, 2H), 1.91 (p, *J* = 7.6 Hz, 2H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 172.0, 150.7, 137.5, 129.4, 125.7, 121.5, 115.6, 33.6, 33.0, 24.0.

HRMS (EI): calcd. For $[C_{12}H_{14}O_2]^+$ 190.0988, found 190.0983.



Phenyl pent-3-enoate (75). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and *trans*-1-bromo-2-butene (81.5 µL, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (61.1 mg, 69% yield, Z : E = 1 : 2.3).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.33 - 7.25 (m, 3H), 7.18 - 7.08 (m, 1.6H), 7.04 - 6.97 (m, 3H), 5.86 - 5.40 (m, 2.8H), 3.26 (dt, *J* = 6.4, 1.0 Hz, 0.87H), 3.18 (dd, *J* = 5.4, 1.3 Hz, 2H), 1.77 - 1.58 (m, 5.1H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 170.5, 170.4, 150.7, 130.1, 129.3, 129.3, 128.2, 125.7, 122.1, 121.5, 121.5, 121.1, 114.6, 38.1, 32.8, 17.9, 13.0.

HRMS (ESI-TOF): calcd. For $[C_{11}H_{12}O_2+H]^+$ 177.0915, found 177.0916.



Phenyl 2-(2-iodophenyl)acetate (76). Prepared according to general procedure using phenol (47.1 mg, 0.5 mmol) and 1-(bromomethyl)-2-iodobenzene (238 mg, 0.8 mmol). The crude product was purified by silica gel chromatography (PE/EA = 20:1) to afford the title compound as a light yellow oil (61.1 mg, 75% yield).

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.93 (d, *J* = 7.9, 1.1 Hz, 1H), 7.48 - 7.37 (m, 4H), 7.36 - 7.18 (m, 1H), 7.19 (dd, *J* = 8.6, 1.2 Hz, 2H), 7.04 (td, *J* = 7.9, 6.9, 2.2 Hz, 1H), 4.09 (s, 2H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 168.8, 150.6, 139.5, 137.2, 130.7, 129.3, 129.0, 128.5, 125.8, 121.4, 100.9, 46.3.

HRMS (EI): calcd. For $[C_{14}H_{11}O_2I_1]^+$ 337.9798, found 337.9791.



Phenyl 2-cyclopropylacetate (81). Prepared according to *Mechanistic Studies*. The yield of **73/81** = 5/1.

^{1}H NMR (300 MHz, $CDCl_3$) δ 7.35 - 7.21 (m, 2.7H), 7.19 - 7.07 (m, 1.4H), 7.06 - 6.94 (m, 2.7H), 6.01 - 5.55 (m, 1H), 5.20 - 4.60 (dd, 2.1H), 2.64 - 2.52 (t, 2.1H), 2.49 - 2.32 (m, 2.5H), 0.65 - 0.40 (m, 0.39H), 0.18 (m, *J* = 6.0 Hz, 0.39H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 171.4, 150.6, 136.3, 129.3, 125.7, 121.5, 115.8, 39.4, 33.6, 28.8, 6.9, 4.4.

HRMS (EI): calcd. For $[C_{11}H_{12}O_2]^+$ 176.0832, found 176.0831.

References

(1) Bernhard. Y.; Winckler, P.; Chassagnon, R.; Richard, P.; Gigot, É.; Perrier-Cornet, J.-M.; Decréau, R. A. Subphthalocyanines: addressing water-solubility, nano-encapsulation, and activation for optical imaging of B16 melanoma cells. *Chem. Commun*. **2014**, *50*, 13975-13978.

(2) Smith, S. M.; Takacs, J. M. Amide-Directed Catalytic Asymmetric Hydroboration of Trisubstituted Alkenes. *J. Am. Chem. Soc*. **2010**, *132*, 1740-1741.

(3) Boto, A.; Hernández, R.; de León, Y.; Murguía, J. R.; Rodriguez-Afonso, A. Synthesis of Functionalized Nitrogen Heterocycles by Radical. *Eur. J. Org. Chem.* **2005**, 673-682.

(4) Xu, H.; Zhao, C.; Qian, Q.; Deng, W.; Gong, H. Nickel-catalyzed cross-coupling of unactivated alkyl halides using bis(pinacolato)diboron as reductant. *Chem. Sci*. **2013**, *4*, 4022-4029.

NMR Spectra


^{1}H NMR (400 MHz, CDCl$_3$)
7.44
7.42
7.40
7.28
7.26
7.24
7.14
7.12
2.62
2.61
2.59
1.83
1.82
1.81
1.80
1.80
1.79
1.78
1.77
1.76
1.55
1.53
1.51
1.49
1.47
1.46
1.04
1.03
1.01
tBu
O
O
3
1.95
0.99
1.91
2.00
2.00
2.03
3.02
f1 (ppm)


^{13}C NMR (101 MHz, CDCl$_3$)
172.14
150.68
129.26
125.57
121.47
77.32 CDCl3
77.00 CDCl3
76.68 CDCl3
34.00
26.91
22.14
13.63
tBu
O
O
3
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
7.08
7.05
6.87
6.85
2.47
2.44
2.42
2.34
1.69
1.67
1.65
1.62
1.59
1.41
1.39
1.36
1.34
1.31
1.29
0.90
0.88
0.85
Me
nBu
4
2.01
2.00
2.08
3.03
2.07
2.12
3.07
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
172.35
148.45
135.16
129.78
121.15
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
34.01
26.95
22.17
20.74
13.64
Me
nBu
4
f1 (ppm)

^{1}H NMR (400 MHz, $CDCl_3$)



^{13}C NMR (101 MHz, $CDCl_3$)




^{1}H NMR (300 MHz, CDCl$_3$)
7.45
7.42
7.07
7.04
2.63
2.60
2.58
1.85
1.83
1.80
1.78
1.75
1.57
1.54
1.52
1.49
1.47
1.44
1.38
1.05
1.03
1.00
nBu
tBu
O
O
6
1.99
1.99
2.00
2.00
2.11
9.00
3.01
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
172.30
148.34
148.31
126.14
120.77
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
34.34
34.03
31.22
26.96
22.16
13.64
nBu
tBu
O
O
6
f1 (ppm)

^{1}H NMR (400 MHz, $CDCl_3$)



^{13}C NMR (101 MHz, $CDCl_3$)



^{1}H NMR (300 MHz, $CDCl_3$)



^{13}C NMR (75 MHz, $CDCl_3$)




^{1}H NMR (400 MHz, CDCl$_3$)
7.14
7.14
7.13
7.13
7.12
7.12
7.10
7.10
7.10
7.06
7.04
7.03
6.87
6.85
2.43
2.42
2.40
1.65
1.64
1.62
1.60
1.58
1.56
1.37
1.35
1.33
1.31
1.29
1.27
0.87
0.85
0.83
Me
Ph
Me
O
O
nBu
9
2.5
2.0
1.5
1.0
0.5
f1 (ppm)
5.95
1.00
2.02
2.01
2.16
5.89
2.03
3.03
.0
10.5
10.0
9.5
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
-0.5
-1
f1 (ppm)


^{13}C NMR (101 MHz, CDCl$_3$)
172.17
150.19
148.46
147.90
127.94
127.91
127.65
126.65
126.63
126.62
125.59
120.75
77.32 CDCl3
77.00 CDCl3
76.68 CDCl3
42.56
33.98
30.72
26.90
22.12
13.64
Me
Ph
Me
O
O
nBu
9
210
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
-1
f1 (ppm)

^{1}H NMR (300 MHz, $CDCl_3$)



^{13}C NMR (75 MHz, $CDCl_3$)




^{1}H NMR (300 MHz, CDCl$_3$)
11
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
11
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
7.45
7.42
7.22
7.19
7.12
7.11
7.10
6.43
6.42
6.41
2.67
2.64
2.62
1.86
1.83
1.81
1.78
1.60
1.57
1.55
1.52
1.50
1.47
1.09
1.06
1.06
nBu
O
N
O
12
7.5 7.4 7.3 7.2 7.1 7.0 6.9 6.8 6.7 6.6 6.5 6.4 6.3 6.2
f1 (ppm)
2.02
1.98
1.93
1.98
2.00
2.03
2.05
3.02
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5 -1
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
172.11
148.21
138.26
122.50
121.33
119.34
110.38
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
33.91
26.84
22.13
13.62
nBu
O
N
O
12
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
f1 (ppm)


7.93
7.92
7.91
7.91
7.90
7.89
7.88
7.86
7.86
7.58
7.57
7.56
7.54
7.52
7.51
7.33
7.31
2.71
2.69
2.67
1.91
1.89
1.87
1.87
1.85
1.83
1.61
1.59
1.57
1.56
1.54
1.52
1.10
1.08
1.07
1H NMR (400 MHz, CDCl3)
nBu
O
O
13
3.07
0.99
2.03
1.00
2.05
2.07
2.07
3.08
f1 (ppm)


13C NMR (101 MHz, CDCl3)
172.29
148.32
133.66
131.29
129.22
127.63
127.48
126.39
125.50
121.10
118.37
77.32 CDCl3
77.00 CDCl3
76.68 CDCl3
34.04
26.92
22.17
13.66
nBu
O
O
13
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
14, 99%
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
14, 99%
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
8.38
8.05
8.05
8.04
8.04
8.02
8.02
8.01
7.99
7.98
7.98
7.96
7.95
7.56
7.54
7.54
7.53
7.52
7.52
7.51
7.51
7.50
7.49
7.49
7.47
7.47
7.26 CDCl3
2.98
2.96
2.93
2.86
2.03
2.01
1.98
1.96
1.70
1.67
1.65
1.62
1.60
1.57
1.13
1.10
1.08
nBu
O
15
8.1
8.0
7.9
7.8
7.7
7.6
7.5
f1 (ppm)
3.0
2.5
2.0
1.5
f1 (ppm)
1.00
3.99
4.10
2.08
2.09
2.11
3.11
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
172.30
142.12
131.81
128.38
126.13
125.45
124.58
123.95
121.31
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
33.96
27.25
22.51
13.78
nBu
O
15
f1 (ppm)

^{1}H NMR (400 MHz, $CDCl_3$)



^{13}C NMR (101 MHz, $CDCl_3$)



^{19}F NMR (282 MHz, $CDCl_3$)



16


^{1}H NMR (400 MHz, CDCl$_3$)
7.37
7.34
7.06
7.04
2.59
2.58
2.56
1.80
1.78
1.76
1.74
1.72
1.51
1.50
1.48
1.46
1.44
1.42
1.02
1.00
0.98
nBu
Cl
O
O
17
1.90
1.92
2.00
2.01
2.04
3.00
f1 (ppm)


^{13}C NMR (101 MHz, CDCl$_3$)
171.87
149.13
130.90
129.29
122.86
77.32 CDCl3
77.00 CDCl3
76.68 CDCl3
33.90
26.81
22.12
13.61
nBu
Cl
O
O
17
f1 (ppm)

^{1}H NMR (400 MHz, $CDCl_3$)



^{13}C NMR (101 MHz, $CDCl_3$)




^{1}H NMR (400 MHz, CDCl$_3$)
8.08
8.06
7.28 CDCl3
7.18
7.15
3.90
2.59
2.57
2.55
1.78
1.76
1.74
1.72
1.70
1.49
1.48
1.46
1.44
1.42
1.40
0.99
0.97
0.95
MeOOC
nBu
O
O
19
1.95
1.95
2.97
2.00
2.02
2.02
3.00
f1 (ppm)


^{13}C NMR (101 MHz, CDCl$_3$)
171.54
166.15
154.30
130.98
127.44
121.48
77.32 CDCl3
77.00 CDCl3
76.68 CDCl3
52.02
33.96
26.76
22.09
13.59
MeOOC
nBu
O
O
19
f1 (ppm)


1H NMR (300 MHz, CDCl3)
7.97
7.94
7.26 CDCl3
7.16
7.13
2.57
2.55
2.53
1.76
1.74
1.72
1.69
1.66
1.48
1.46
1.43
1.41
1.38
1.36
0.97
0.94
0.92
nBu
Ac
O
O
20
f1 (ppm)
1.97
1.95
4.92
2.00
2.02
2.97
f1 (ppm)


13C NMR (75 MHz, CDCl3)
196.65
171.53
154.35
134.46
129.75
121.62
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
33.93
26.73
26.41
22.06
13.57
nBu
Ac
O
O
20
f1 (ppm)


^{1}H NMR (400 MHz, CDCl$_3$)
9.96
7.90
7.88
7.26
7.24
2.59
2.57
2.55
1.77
1.75
1.73
1.71
1.69
1.48
1.46
1.44
1.42
1.41
1.39
0.97
0.96
0.94
OHC
nBu
O
21
f1 (ppm)
0.90
1.92
1.90
2.00
2.12
2.10
3.12


^{13}C NMR (101 MHz, CDCl$_3$)
190.75
171.37
155.31
133.72
130.98
122.19
77.32 CDCl3
77.00 CDCl3
76.68 CDCl3
33.88
26.67
22.02
13.53
OHC
nBu
O
21
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
7.69
7.66
7.24
7.21
2.61
2.59
2.55
1.76
1.74
1.71
1.69
1.51
1.48
1.46
1.45
1.43
1.41
1.38
0.99
0.97
0.94
NC
O
^{n}Bu
22
2.00
2.03
2.00
2.06
2.06
3.05
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
171.20
153.89
133.45
122.60
118.10
109.39
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
33.84
26.62
22.01
13.52
NC
O
^{n}Bu
22
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
8.30
8.17
7.22
7.18
2.56
2.53
2.51
1.73
1.70
1.68
1.65
1.63
1.44
1.42
1.39
1.37
1.34
1.32
0.93
0.90
0.88
^{t}Bu
O_2N
23
1.91
2.03
2.00
1.98
2.03
2.99
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
171.30
155.53
145.24
125.17
122.43
77.47 CDCl3
77.04 CDCl3
76.62 CDCl3
34.05
26.79
22.20
13.69
^{t}Bu
O_2N
23
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
nBu
Me
24
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
nBu
Me
24
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
7.26 CDCl3
7.07
7.06
7.03
6.94
6.91
2.64
2.62
2.59
2.35
2.19
1.86
1.84
1.82
1.79
1.76
1.57
1.55
1.52
1.50
1.47
1.45
1.06
1.03
1.01
nBu
Me
Me
O
O
25
f1 (ppm)
0.97
1.00
0.98
2.00
3.03
2.98
2.00
2.04
3.02
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
171.99
147.04
135.26
131.57
129.47
127.27
121.41
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
33.84
27.04
22.21
20.64
15.97
13.60
nBu
Me
Me
O
O
25
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
26
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
172.23
148.05
140.00
126.47
126.06
122.19
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
33.98
27.25
26.99
22.83
22.22
13.62
26
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
27
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
27
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
7.26 CDCl3
7.19
7.05
7.02
6.89
6.87
2.64
2.61
2.59
2.35
1.85
1.82
1.80
1.77
1.74
1.55
1.52
1.50
1.48
1.47
1.46
1.45
1.36
1.03
1.00
0.98
Me
tBu
nBu
28
0.98
1.00
1.01
2.00
3.05
2.00
1.98
8.91
3.07
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
172.50
146.95
140.47
134.89
127.79
127.28
123.67
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
34.66
34.30
30.19
29.54
26.81
22.31
21.14
13.71
Me
tBu
nBu
28
f1 (ppm)


^{1}H NMR (400 MHz, CDCl$_3$)
29
f1 (ppm)


^{13}C NMR (101 MHz, CDCl$_3$)
171.95
147.74
137.53
134.92
130.71
128.86
128.33
128.06
127.25
126.68
122.74
77.32 CDCl3
77.00 CDCl3
76.68 CDCl3
33.76
26.60
21.92
13.55
29
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
7.26 CDCl3
7.13
7.11
7.10
7.10
7.10
2.68
2.66
2.63
2.21
1.90
1.87
1.85
1.82
1.79
1.59
1.57
1.54
1.52
1.49
1.47
1.07
1.04
1.02
Me
nBu
O
O
Me
30
2.6 2.4 2.2 2.0 1.8 1.6 1.4 1.2 1.0
f1 (ppm)
2.90
2.00
5.93
2.00
2.05
3.00
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
171.33
148.13
129.96
128.43
125.60
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
33.65
27.10
22.31
16.22
13.61
Me
nBu
O
O
Me
30
f1 (ppm)

^{1}H NMR (300 MHz, $CDCl_3$)



^{13}C NMR (75 MHz, $CDCl_3$)




^{1}H NMR (300 MHz, CDCl$_3$)
7.80
7.78
7.60
7.57
7.57
7.55
7.54
7.52
7.47
7.45
7.42
7.35
7.32
7.30
7.22
7.19
2.22
2.19
2.17
1.51
1.49
1.46
1.44
1.41
1.32
1.29
1.27
1.24
1.22
1.20
0.88
0.85
0.83
COPh
nBu
O
O
32
1.96
1.97
2.00
1.00
0.99
2.00
2.01
2.17
3.08
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
194.60
171.54
148.49
137.36
132.87
131.92
131.58
130.12
129.62
128.21
125.44
123.01
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
33.38
26.19
21.91
13.48
COPh
nBu
O
O
32
f1 (ppm)


10.06
7.83
7.83
7.81
7.81
7.58
7.58
7.57
7.56
7.56
7.55
7.54
7.34
7.34
7.32
7.32
7.30
7.30
7.12
7.10
2.62
2.60
2.58
1.75
1.73
1.71
1.69
1.68
1.45
1.43
1.41
1.39
1.37
1.36
0.94
0.92
0.90
1H NMR (400 MHz, CDCl3)
CHO
nBu
O
O
33
1.01
1.00
1.03
1.03
1.01
2.09
2.14
2.24
3.20
f1 (ppm)


13C NMR (75 MHz, CDCl3)
188.62
172.01
151.83
135.26
130.77
128.11
126.30
123.47
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
33.87
26.78
22.27
13.71
CHO
nBu
O
O
33
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
10.06
7.73
7.71
7.53
7.50
7.34
7.32
7.29
2.74
2.72
2.69
2.24
1.87
1.85
1.82
1.80
1.77
1.56
1.54
1.51
1.49
1.46
1.44
1.04
1.01
0.99
CHO
nBu
O
O
Me
34
0.94
0.97
0.98
1.07
2.00
3.06
2.02
2.08
3.07
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
189.04
171.70
150.11
136.92
132.06
129.22
128.24
126.12
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
33.63
26.80
22.32
15.76
13.68
CHO
nBu
O
O
Me
34
f1 (ppm)


7.18 7.18 7.16 7.15 7.15 7.13 7.11 7.09 7.09 7.06 6.95 6.94 6.93 5.89 5.89 5.87 5.85 5.85 5.84 5.80 5.80 5.79 5.79 5.78 5.78 5.76 5.01 5.00 4.98 4.97 4.97 4.96 4.95 4.95 4.94 4.93
3.23 3.20
2.51 2.49 2.46 1.72 1.70 1.67 1.64 1.62 1.43 1.41 1.38 1.36 1.33 1.31 0.92 0.89 0.87
^{1}H NMR (300 MHz, CDCl$_3$)
Allyl
O
nBu
O
35
3.05 1.00 0.96 1.99 2.02 2.02 2.05 2.09 3.08
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
172.07 148.93 135.87 131.84 130.29 127.22 125.90 122.33 116.13
77.42 CDCl3 77.00 CDCl3 76.58 CDCl3
34.50 33.98 26.98 22.27 13.68
Allyl
O
nBu
O
35
f1 (ppm)

^{1}H NMR (400 MHz, $CDCl_3$)



^{13}C NMR (101 MHz, $CDCl_3$)




^{1}H NMR (400 MHz, CDCl$_3$)
Ac
^{n}Bu
37
f1 (ppm)


^{13}C NMR (101 MHz, CDCl$_3$)
Ac
^{n}Bu
37
f1 (ppm)


^{1}H NMR (400 MHz, CDCl$_3$)
38
f1 (ppm)


^{13}C NMR (101 MHz, CDCl$_3$)
38
f1 (ppm)

^{19}F NMR (282 MHz, $CDCl_3$)



38

^{1}H NMR (400 MHz, $CDCl_3$)



^{13}C NMR (101 MHz, $CDCl_3$)



^{19}F NMR (282 MHz, $CDCl_3$)



39


7.44
7.44
7.42
7.42
7.41
7.41
7.40
7.40
7.39
7.34
7.34
7.32
7.32
7.32
7.32
7.31
7.30
7.29
7.28
7.27
7.27
7.19
7.16
2.34
2.32
2.30
1.53
1.51
1.48
1.46
1.43
1.39
1.27
1.25
1.22
1.20
1.18
0.89
0.86
0.84
1H NMR (300 MHz, CDCl3)
nBu
O
O
nBu
O
O
40
2.4 2.2 2.0 1.8 1.6 1.4 1.2 1.0 0.8
f1 (ppm)
1.95
3.91
1.93
4.00
3.98
4.30
6.21
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5
f1 (ppm)


13C NMR (75 MHz, CDCl3)
171.92
148.19
131.14
130.61
128.78
125.69
122.36
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
33.67
26.65
21.93
13.61
nBu
O
O
nBu
O
O
40
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
f1 (ppm)

^{1}H NMR (300 MHz, $CDCl_3$)



^{13}C NMR (75 MHz, $CDCl_3$)



^{1}H NMR (300 MHz, $CDCl_3$)



42

^{13}C NMR (75 MHz, $CDCl_3$)



42


^{1}H NMR (400 MHz, CDCl$_3$)
43
f1 (ppm)


^{13}C NMR (101 MHz, CDCl$_3$)
43
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
8.35
7.38
7.38
7.37
7.37
7.26 CDCl3
7.15
7.12
7.02
7.01
7.00
6.91
6.90
6.88
6.88
6.51
6.50
6.50
6.49
6.49
6.49
2.70
2.67
2.65
1.91
1.88
1.86
1.83
1.81
1.61
1.58
1.56
1.56
1.53
1.51
1.49
1.09
1.06
1.04
tBu
O
O
N
H
44
8.5
8.0
7.5
7.0
6.5
f1 (ppm)
1.00
1.02
1.06
1.04
1.05
1.04
2.09
2.14
2.11
3.13
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
173.66
144.03
133.54
127.86
125.70
115.57
112.19
111.53
102.10
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
34.06
27.02
22.15
13.63
tBu
O
O
N
H
44
f1 (ppm)

^{1}H NMR (400 MHz, $CDCl_3$)



^{13}C NMR (101 MHz, $CDCl_3$)



^{1}H NMR (300 MHz, $CDCl_3$)



^{13}C NMR (75 MHz, $CDCl_3$)




^{1}H NMR (400 MHz, CDCl$_3$)
7.60
7.58
6.78
6.76
2.48
2.46
2.45
2.44
1.68
1.66
1.64
1.62
1.61
1.40
1.38
1.36
1.34
1.32
1.31
0.90
0.88
0.86
nBu
I
47
f1 (ppm)
1.79
1.81
2.00
2.00
2.03
3.04
f1 (ppm)


^{13}C NMR (101 MHz, CDCl$_3$)
171.80
150.51
138.33
123.73
89.62
77.32 CDCl3
77.00 CDCl3
76.68 CDCl3
33.98
26.84
22.16
13.67
nBu
I
47
f1 (ppm)

^{1}H NMR (400 MHz, $CDCl_3$)



^{13}C NMR (101 MHz, $CDCl_3$)




^{1}H NMR (300 MHz, CDCl$_3$)
7.26 CDCl3
4.56
4.54
4.51
4.49
2.52
2.50
2.47
2.12
1.71
1.68
1.66
1.63
1.61
1.46
1.44
1.41
1.39
1.36
1.34
1.31
0.93
0.90
0.88
Me
Me
O
O
O
^{n}Bu
49
4.55 4.50 4.45 4.40
f1 (ppm)
1.7 1.6 1.5 1.4 1.3
f1 (ppm)
0.88
1.99
2.87
2.08
3.01
2.00
3.17
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5 -1
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
195.71
179.79
170.38
128.90
81.19
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
33.06
26.74
21.99
16.20
13.88
13.52
Me
Me
O
O
O
^{n}Bu
49
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -2
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
7.26 CDCl3
6.77
6.74
6.60
6.59
6.53
6.52
6.50
6.49
5.95
3.54
3.52
2.52
2.49
1.77
1.75
1.72
1.70
1.67
1.49
1.47
1.44
1.42
1.40
1.37
0.99
0.99
0.96
0.96
0.94
tBu
50
1.00
0.97
1.01
2.04
2.05
2.10
2.11
3.11
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
172.43
147.86
145.14
144.96
113.76
107.79
103.63
101.55
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
33.86
26.87
22.12
13.59
tBu
50
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
7.29
7.26
6.86
6.83
6.81
2.92
2.92
2.90
2.89
2.57
2.54
2.52
2.48
2.46
2.38
2.37
2.32
2.30
2.27
2.27
2.24
2.20
2.17
2.14
2.11
2.09
2.08
2.06
2.04
2.03
2.01
1.98
1.97
1.95
1.94
1.93
1.79
1.77
1.74
1.69
1.67
1.65
1.63
1.59
1.56
1.55
1.53
1.51
1.49
1.44
1.41
1.39
1.37
1.08
0.97
0.95
0.91
nBu
51
7.3 7.2 7.1 7.0 6.9 6.8
f1 (ppm)
2.95 2.90 2.85
f1 (ppm)
2.6 2.4 2.2 2.0 1.8 1.6 1.4
f1 (ppm)
1.00 0.95 0.90
f1 (ppm)
1.05
1.00
1.00
1.99
4.03
5.14
10.35
3.07
3.04
.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5 -1
f1 (ppm)


^{13}C NMR (101 MHz, CDCl$_3$)
220.47
172.36
148.47
137.75
137.05
126.18
121.42
118.60
77.32 CDCl3
77.00 CDCl3
76.68 CDCl3
50.24
47.75
43.97
37.83
35.68
33.95
31.39
29.23
26.89
26.18
25.59
22.10
21.42
13.66
13.61
nBu
51
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -1
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
7.26 CDCl3
52
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
172.22
149.26
140.47
126.61
124.81
122.90
117.22
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
52
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
53
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
53
f1 (ppm)

^{19}F NMR (282 MHz, $CDCl_3$)




^{1}H NMR (300 MHz, CDCl$_3$)
7.47
7.46
7.45
7.44
7.42
7.42
7.42
7.32
7.30
7.27
7.23
7.21
7.19
7.05
7.02
2.17
O
Me
O
Ph
54
7.5
7.4
7.3
7.2
7.1
7.0
6.9
f1 (ppm)
4.02
2.02
1.01
2.01
3.00
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
169.36
149.98
140.21
138.83
128.67
128.03
127.22
126.98
121.73
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
20.99
O
Me
O
Ph
54
f1 (ppm)


1H NMR (300 MHz, CDCl3)
7.44
7.42
7.39
7.38
7.26
7.24
7.14
7.12
2.67
2.64
2.62
2.59
1.33
1.31
1.28
Et
O
O
55
1.97
1.00
1.95
2.00
3.09
f1 (ppm)


13C NMR (75 MHz, CDCl3)
172.82
150.71
129.28
125.59
121.47
77.42 CDCl3
77.00 CDCl3
76.57 CDCl3
27.65
8.98
Et
O
O
55
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
7.44
7.42
7.39
7.38
7.26
7.23
7.15
7.12
2.63
2.60
2.58
1.86
1.84
1.81
1.79
1.76
1.50
1.48
1.47
1.45
1.43
1.42
1.38
1.37
0.99
0.97
0.94
Me
56
2.6 2.4 2.2 2.0 1.8 1.6 1.4 1.2 1.0
f1 (ppm)
2.01
1.01
1.98
2.02
2.02
10.90
3.21
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
172.06
150.70
129.22
125.52
121.45
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
34.26
31.71
29.13
29.03
29.00
24.84
22.55
13.98
Me
56
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
7.44
7.42
7.39
7.38
7.26
7.23
7.15
7.12
2.62
2.60
2.57
1.86
1.84
1.82
1.81
1.79
1.77
1.50
1.47
1.45
1.43
1.40
1.37
1.34
0.98
0.96
0.93
Me
57
2.00
1.00
2.00
2.02
2.05
31.64
3.25
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
172.06
150.74
129.24
125.54
121.49
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
34.31
31.90
29.68
29.64
29.57
29.44
29.35
29.23
29.07
24.90
22.65
14.05
Me
57
f1 (ppm)

^{1}H NMR (300 MHz, $CDCl_3$)



^{13}C NMR (75 MHz, $CDCl_3$)




1H NMR (300 MHz, CDCl3)
7.46
7.46
7.43
7.41
7.36
7.34
7.30
7.30
7.28
7.26
7.26
7.25
7.13
7.11
4.13
4.11
4.08
2.63
2.60
2.59
2.59
2.58
2.55
Ph
Ph
O
O
59
12.94
1.99
1.00
3.99
f1 (ppm)


13C NMR (75 MHz, CDCl3)
171.80
150.60
143.90
129.34
128.57
127.82
126.42
125.70
121.47
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
50.41
32.80
30.47
Ph
Ph
O
O
59
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
7.32
7.30
7.27
7.16
7.14
7.11
7.01
6.99
2.97
2.94
2.91
2.89
2.86
1.97
1.95
1.92
1.92
1.92
1.90
1.90
1.89
1.71
1.70
1.70
1.68
1.61
1.61
1.60
1.58
1.58
1.58
60
3.0
2.9
2.8
f1 (ppm)
2.05
1.10
2.07
1.00
10.84
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
175.24
150.92
129.32
125.58
121.52
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
43.86
30.07
25.88
60
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
61
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
61
f1 (ppm)

^{19}F NMR (282 MHz, $CDCl_3$) δ -66.26.



61

^{1}H NMR (300 MHz, $CDCl_3$)



62

^{13}C NMR (75 MHz, $CDCl_3$)



62


^{1}H NMR (300 MHz, CDCl$_3$)
63
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
63
f1 (ppm)

^{1}H NMR (300 MHz, $CDCl_3$)



^{13}C NMR (75 MHz, $CDCl_3$) δ 171.3, 166.0, 150.6, 137.8, 131.1, 129.5, 129.4, 125.9, 121.5, 100.9, 64.1, 31.1, 24.1.



^{1}H NMR (300 MHz, $CDCl_3$)



65

^{13}C NMR (75 MHz, $CDCl_3$)



65


^{1}H NMR (400 MHz, CDCl$_3$)
7.43
7.42
7.40
7.28
7.26
7.24
7.14
7.12
2.62
2.60
2.58
1.84
1.83
1.81
1.79
1.77
1.51
1.49
1.47
1.46
1.45
1.41
1.40
1.40
1.39
1.37
1.36
1.36
0.99
0.97
0.96
Me
66
1.8 1.7 1.6 1.5 1.4 1.3 1.2 1.1 1.0 0.9 0.8
f1 (ppm)
1.92
0.98
1.92
2.00
2.07
6.25
3.27
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5
f1 (ppm)


^{13}C NMR (101 MHz, CDCl$_3$)
172.11
150.69
129.24
125.54
121.46
77.32 CDCl3
77.00 CDCl3
76.68 CDCl3
34.27
31.35
28.67
24.81
22.39
13.92
Me
66
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -1
f1 (ppm)


^{1}H NMR (400 MHz, CDCl$_3$)
7.43
7.41
7.39
7.27
7.26
7.24
7.13
7.11
2.60
2.58
2.56
1.84
1.82
1.80
1.78
1.76
1.69
1.67
1.65
1.64
1.62
1.37
1.36
1.36
1.35
1.35
1.33
1.33
1.32
0.98
0.96
Me
Me
O
O
67
1.9
1.8
1.7
1.6
1.5
1.4
1.3
f1 (ppm)
1.96
1.02
1.93
2.00
2.10
1.21
2.19
3.05
3.01
f1 (ppm)


^{13}C NMR (101 MHz, CDCl$_3$)
172.18
150.70
129.30
125.61
121.51
77.32 CDCl3
77.00 CDCl3
76.68 CDCl3
38.26
34.54
27.72
22.78
22.43
Me
Me
O
O
67
f1 (ppm)


¹H NMR (400 MHz, CDCl₃)
7.30
7.28
7.26
7.14
7.12
7.10
7.00
6.98
2.49
2.47
2.45
1.70
1.69
1.66
1.65
1.60
1.58
1.56
1.55
1.23
1.22
1.22
1.18
1.16
1.15
1.12
1.09
1.06
0.91
0.88
0.85
0.82
68
7.30 7.25 7.20 7.15 7.10 7.05 7.00 6.95
f1 (ppm)
2.50 2.45 2.40
f1 (ppm)
1.7 1.6 1.5 1.4 1.3 1.2 1.1 1.0 0.9 0.8 0.7
f1 (ppm)
2.04
1.07
2.01
2.10
7.62
4.45
2.38
f1 (ppm)


¹³C NMR (101 MHz, CDCl₃)
172.54
150.73
129.31
125.62
121.51
77.32 CDCl3
77.00 CDCl3
76.68 CDCl3
37.22
34.84
32.26
31.99
26.47
26.20
68
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
Me
Me
Me
O
O
69
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
172.42
150.74
129.29
125.59
121.50
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
39.18
36.86
32.39
29.15
31.84
27.90
24.65
22.64
22.55
19.26
Me
Me
Me
O
O
69
f1 (ppm)

^{1}H NMR (400 MHz, $CDCl_3$)



70

^{13}C NMR (101 MHz, $CDCl_3$)



70


^{1}H NMR (300 MHz, CDCl$_3$)
7.43
7.40
7.38
7.28
7.25
7.23
7.11
7.09
2.65
2.62
2.60
2.42
2.39
2.37
1.95
1.93
1.93
1.93
1.92
1.91
1.90
1.89
1.88
1.87
1.86
1.85
1.85
1.82
1.81
1.81
1.79
1.78
1.78
1.76
1.75
1.75
1.73
O
O
CN
71
1.99
1.01
1.95
2.00
2.01
2.00
2.08
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
171.07
150.37
129.26
125.70
121.29
119.18
77.43 CDCl3
77.00 CDCl3
76.58 CDCl3
33.13
24.55
23.62
16.76
O
O
CN
71
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
72
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
169.94
150.62
129.63
129.40
125.85
121.46
119.17
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
39.12
72
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
73
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
171.39
150.63
136.24
129.30
125.67
121.47
115.82
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
33.53
28.81
73
f1 (ppm)

^{1}H NMR (400 MHz, $CDCl_3$)



^{13}C NMR (101 MHz, $CDCl_3$)




^{1}H NMR (300 MHz, CDCl$_3$)
Me
75
Z:E=1:2.3
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
Me
75
Z:E=1:2.3
f1 (ppm)


^{1}H NMR (300 MHz, CDCl$_3$)
7.95
7.95
7.92
7.92
7.44
7.42
7.42
7.39
7.37
7.29
7.27
7.24
7.21
7.21
7.18
7.18
7.07
7.06
7.04
7.04
7.04
7.03
7.02
7.01
4.09
O
O
I
76
7.5
7.4
7.3
7.2
7.1
7.0
f1 (ppm)
1.02
3.96
1.04
1.94
1.19
2.00
f1 (ppm)


^{13}C NMR (75 MHz, CDCl$_3$)
168.80
150.62
139.47
137.23
130.72
129.28
129.04
128.46
125.80
121.39
100.94
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
46.29
O
O
I
76
f1 (ppm)


1H NMR (300 MHz, CDCl3)
73, 74%
81, 15%
f1 (ppm)


13C NMR (75 MHz, CDCl3)
171.42
150.64
136.25
129.32
125.69
121.49
115.85
77.42 CDCl3
77.00 CDCl3
76.58 CDCl3
39.38
33.56
28.83
6.86
4.38
73, 74%
81, 15%
f1 (ppm)